cancer hates us - bswhealth
TRANSCRIPT
CANCER HATES USTM
2019 Annual Report
CANCER HATES PIONEERS
Because we provide warriors with an arsenal of tools to defeat cancer—including immunotherapies that re-engineer your existing cells, giving your body the power to fight cancer from the inside. See all the reasons why cancer hates pioneers at CancerHatesPioneers.com.
CONTENTS
BAYLOR SCOTT & WHITE ONCOLOGY Cancer research studies at Baylor Scott & White Charles A. Sammons Cancer Center, located on the campus of Baylor University Medical Center, part of Baylor Scott & White Health, are conducted through Baylor Scott & White Research Institute, Texas Oncology and The US Oncology Network.
HOSPITAL-BASED CANCER PROGRAMSBaylor Scott & White has the largest network of hospital-based cancer programs in Texas with 16 cancer centers.
Baylor Scott & White is the third largest network of cancer centers accredited by the Commission on Cancer in the nation.
10 North TexasLocations Carrollton
Dallas
Frisco
Fort WorthGrapevine
IrvingLake Pointe
McKinneyPlano
Waxahachie
6 Central TexasLocations
College Station
KilleenMarble Falls
Round Rock
TempleWaco
Letter from Ronan Kelly, MD, MBA ...................................................... 4
Cancer research and treatment centers .....................................6
High-risk breast screening program ..............................................6
Arts in Medicine .............................................................................................. 8
Breast cancer patient draws confidence, .................................. 8 courage from our Patient Resource Center’s programs and services
Patient Resource Center – ..................................................................10 Arts in Medicine statistics
Blood and marrow transplant program update ...................... 11
Innovations in research............................................................................12
Immunotherapy continues to be a primary ..............................12 research focus
Observational study of sentinel lymph........................................ 15 node biopsy in patient with melanoma: false negative sentinel lymph node rate
Creating living drugs in the most experienced ..................... 19 cGMP cell manufacturing facility in North Texas
Community outreach and support .................................................23
Catrina Allen, RN, genetics counseling patient .....................23
Patient navigation program sees ....................................................25 significant growth
Oncology education ................................................................................. 26
Pamela Hoof, MD, third-year oncology fellow ...................... 26
Philanthropy ...................................................................................................28
Groundbreaking held for Gene and Jerry Jones .................28 Family Hope Lodge
Patient profiles: Jeff York......................................................................30
Patient profiles: Denise Robertson.................................................32
Swim Across America Dallas event ...............................................33
Celebrating Women luncheon turns 20 .................................... 34
Baylor Scott & White Dallas Foundation funds ......................35 triple negative breast cancer clinical trial
Cancer registry ........................................................................................... 36
2019 publications from Sammons Cancer Center ............... 38
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
3
Welcome to the 2019 Baylor University Medical Center Oncology Annual Report, where we highlight many of the achievements over the last year in one of the largest cancer treatment centers in the United States—Baylor Scott & White Charles A. Sammons Cancer Center – Dallas and Baylor Scott & White T. Boone Pickens Cancer Hospital. Much of the industry-leading progress we are making is rooted in robust research conducted by oncologists and scientists located on the Baylor University Medical Center campus in Dallas, TX.
Since coming to Baylor Dallas in the fall of 2018, I have been gratified to learn that we don’t just focus on treating a patient’s cancer—we treat the whole individual including his or her physical, emotional and spiritual needs. This patient-centered approach is not the norm throughout the United States, but it is here, and it is what differentiates us.
I came to Baylor Dallas from Johns Hopkins, where I was the director of oncology for the Gastroesophageal Cancer Therapeutics Program and the medical director of global oncology for Johns Hopkins International. For many years, my passion has been the rapidly emerging field of immuno-oncology, the use of a patient’s own immune cells to fight cancer. Significant advances have been made over the last five to 10 years, but we are just at the start of this exciting new era. Baylor Scott & White has 16 cancer centers throughout Texas (3rd largest Commission on Cancer hospital network in the US). By linking all of these facilities, which span a geographical footprint stretching from Dallas to Fort Worth to Temple and down to Austin, we can make major cancer discoveries across a real-world population of Texans. We are instilling a common theme of “Caring for Every Patient and Learning from Every Patient.”
The big picture of cancer care at Baylor Dallas is breathtaking in terms of breadth, scope and dedicated resources. Few healthcare organizations can offer patients what we do, all on one centralized campus:
• The only dedicated cancer hospital in North Texas—Pickens Cancer Hospital—and one of the largest cancer outpatient centers in the nation—Baylor Scott & White Sammons Cancer Center.
• The only 24-hour urgent care service specifically for cancer patients in North Texas.
• Swim Across America Innovative Clinical Trials Center sponsoring an active roster of immunotherapy and other cancer-related studies and trials.
• The Gene and Jerry Jones American Cancer Society Hope Lodge (opening in 2021) providing 16,000 nights of free lodging annually for cancer patients and their families.
• Through Baylor Scott & White Research Institute (BSWRI) our program features the only good manufacturing practice (GMP) facility in North Texas aligned with a hospital system, which produces human cellular products for novel immunotherapy phase I and II clinical trials. Many of these trials are first-in-human studies and are not available anywhere else in the world. We are committed to a process of continual innovation as we seek to offer our patients the most novel and exciting next-generation treatments for cancer.
LETTER FROM RONAN KELLY, MD, MBA
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT4
• Patient Resource Center offering innovative programs specifically to help cancer patients deal with their disease and recovery. These include art therapy, music therapy, psycho-oncology programs, a chef-led cooking class to help regain weight and to learn how to prepare foods that are tolerable post-surgery or radiation, FitSteps personalized exercise program to help patients regain muscle strength, and ReVitalTM Cancer Rehabilitation, which offers a one-stop shop of physical therapy, occupational therapy and speech therapy programs all under one roof. At Baylor Scott & White, we aim to not only treat a patient’s cancer but to do so in an environment that helps cater to the emotional and psychological needs that a cancer diagnosis can create for a patient and his or her caregivers.
What’s in the future for cancer patients and their families who turn to Baylor Scott & White Sammons Cancer Center for compassion and care? Our cancer center has become a destination location in the United States for next-generation cellular immunotherapy clinical trials including CAR-T, TCR and NK cellular studies. Next year, BSWRI’s GMP facility will also connect to the new Hope Lodge so patients who travel long distances for treatment can avail themselves of advanced care without having to worry about the costs of accommodations.
Additionally, Baylor Scott & White Research Institute is creating the Texas Immuno-Oncology Biorepository through which we can collectively begin to better understand the evolving immune microenvironment of patients who receive FDA-approved immunotherapeutics. This will help put us directly at the epicenter of cancer discoveries, allow us to identify resistance mechanisms that tumors use to overcome immune attack, and enable us to help inform the future design of next-generation strategies to overcome this resistance.
You may have seen our new marketing campaign, Cancer Hates Us, which is also featured in various sections of this report. The campaign features real patients and employees throughout our hospital system in Texas and celebrates our patients, clinical teams and medical advancements. Through powerful messages such as “Cancer Hates Fighters,” “Cancer Hates Defenders” and “Cancer Hates Pioneers,” we hope to raise awareness about the scientific breakthroughs available to cancer patients today and encourage more to seek screenings for early detection. Collaborations with major organizations such as the Dallas Cowboys are helping us with this mission of reaching into every home to say we are here to help.
While these multimillion-dollar investments in facilities, technologies and staff are critically important, we never lose sight of the one reason we are in this fight—our patients. Through their personal stories in this report, you’ll learn how we are by their sides during every step in their cancer journey. After all, when they’re in this battle, they need to know that Baylor Dallas will bring it all to the fight.
Ronan Kelly, MD, MBAChief of Oncology, Baylor Scott & White Health - North TexasMedical Director, Baylor Scott & White Charles A. Sammons Cancer Center
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
5
HIGH-RISK BREAST SCREENING PROGRAM
The Darlene G. Cass Women’s Imaging Center at Baylor University Medical Center launched a High-Risk Breast Screening Program in 2019. The program combines current knowledge about a patient’s breast health from screening mammograms, breast self-exam and more with an in-depth look at her/his personal health history and that of her/his family. This information is matched to predictive evidence-based risk evaluation models developed by the American Cancer Society, National Comprehensive Cancer Network and others. The goal is to help those identified as being at high risk to implement risk-reducing strategies aimed at preventing cancer, or diagnosing the disease at the earliest possible moment, leading to improved outcomes.
CANCER RESEARCH AND TREATMENT CENTERS
DEFENDER Zeeshan Shah, MD, physician on the medical staff of Baylor Dallas and Medical Director of Breast Imaging
6BA
YLO
R U
NIV
ERSI
TY M
EDIC
AL
CEN
TER
20
19 O
NC
OLO
GY
AN
NUA
L RE
PORT
“Most patients underestimate their risk, and many assume that breast cancer is hereditary when, in fact, only 10% of breast cancers fall into that category,” says Zeeshan Shah, MD, a physician on the medical staff of Baylor Dallas and medical director of breast imaging. “The breast cancer specialists at the Darlene G. Cass Women’s Imaging Center believe that knowledge is power, especially when it comes to breast cancer risk. Being aware of certain key factors in the patient’s health history can provide a roadmap to help the patient and the patient’s physician identify the potential for developing breast cancer.”
Participation in the High-Risk Breast Screening Program generally follows an evaluation of a screening mammogram and responses the patient provides on a questionnaire. If the patient meets the criteria for participation in the program, an advanced nurse practitioner experienced in working with high-risk patients will contact the patient to coordinate the process under the guidance of a physician specialized in breast imaging.
The High-Risk Breast Screening Program includes:
• A comprehensive assessment of the patient’s personal health history and the patient’s family history of breast cancer.
• Additional screening tests, if warranted, including ultrasound or MRI.
• Genetic counseling and education, if appropriate, with a genetic specialist about the patient’s risk of developing breast cancer and potential implication for family members. Depending on the patient’s circumstance, this may lead to genetic testing that analyzes DNA from the patient’s cells and identifies the presence of chromosomal abnormalities known as BRCA mutations. Patients with BRCA mutations have a very high risk of developing breast cancer during their lifetime as well as an increased risk for developing ovarian cancer.
• A personalized monitoring plan.
• Prevention strategies that may include surveillance, risk-reduction surgery or drug therapy.
• The opportunity to enroll in appropriate breast cancer research studies or clinical trials.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
7
BREAST CANCER PATIENT DRAWS CONFIDENCE, COURAGE FROM OUR PATIENT RESOURCE CENTER’S PROGRAMS AND SERVICES
Facing a daunting diagnosis of inflammatory breast cancer at 47 years of age, Lisa Williams resolved to stay positive, drawing strength and confidence from other women who had faced the same diagnosis. During her cancer journey, she learned a lot about her fortitude, her faith, and her ability to laugh and have fun.
Inflammatory breast cancer is a rare, aggressive type of cancer, often metastasizing to other organs and generally requiring an intensive regimen of chemotherapy, surgery and radiation. That was Lisa’s experience with the cancer spreading to her liver.
ARTS IN MEDICINE
FIGHTERLisa Williams, breast cancer patient
8BA
YLO
R U
NIV
ERSI
TY M
EDIC
AL
CEN
TER
20
19 O
NC
OLO
GY
AN
NUA
L RE
PORT
“The diagnosis just came out of the blue,” says Lisa. “There’s not an extensive history of cancer in my family. My father had lymphoma when I was five, but he went into remission and never had a reoccurrence. He’s still living and thriving. My mom’s sister had breast cancer, but she also survived. On the recommendation of my oncologist, I had genetic testing to see if I had an abnormal gene, but the tests came back negative.”
Lisa explains that she first learned about the Patient Resource Center in her oncologist’s office. “I saw flyers about the different programs and resources the center offers, and I zeroed in on one about the inflammatory breast cancer support group. Going from having no history of health problems to a serious diagnosis, I knew I wanted to be with other ladies that had the disease.”
The first time she walked into the support group, she immediately noticed the women looked happy, healthy and strong. “Just seeing how they were thriving after treatment brought me a tremendous
amount of confidence, lifted my spirits and boosted my self-esteem,” she says. “This was just before I began my six rounds of chemotherapy. The support group meant so much to me during my treatment and recovery. I’ve become friends with several of the support group participants.”
During her lengthy treatment regimen, Lisa realized that her whole life wasn’t just about cancer. “I learned from the women in the support group that finding a diversion from the daily fight against the disease was an important part of a successful recovery. That’s when I heard about the ukulele group at the center. I decided to join the class, and I took eight weeks of lessons. I discovered my fellow ukulele players were battling a variety of cancers. Besides the disease, the one thing that bonded us was the commitment to have fun. I’m from Colorado, and a few months ago when I visited my family, I took my ukulele and serenaded them. They loved it!”
Lisa says her husband, her two children and three grandchildren have been her support and inspiration. In addition to honing her ukulele skills, she enjoys reading and working with people. She and her husband have worked in ministries with inner-city children for many years, and she says she loves encouraging young people to pursue their dreams and goals.
“My philosophy through my cancer journey was to focus on the positive, learn about people who were winning their fight against serious illness, and to trust the word of God about health, healing and victory,” says Lisa. “I couldn’t have had a better experience than the one I had at Baylor Scott & White. Everyone on staff from my oncologist to my infusion nurse to the licensed clinical psychologist was incredible and compassionate.”
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
9
PATIENT RESOURCE CENTER – ARTS IN MEDICINE STATISTICS
Baylor Scott & White’s triad approach to cancer care—treating body, mind and spirit —creates the optimum opportunity for patients to achieve their highest levels of well-being. The Patient Resource Center at Baylor Scott & White Sammons Cancer Center provides cancer education and support to help patients and their families understand and manage their physical, emotional and spiritual challenges.
Baylor Scott & White Sammons Cancer Center has been a leader in providing cancer patients with outlets for creative expression through the unique Arts in Medicine program. Music, art and more contribute to the patients’ healing process by alleviating emotional distress, enhancing physical health, addressing the sensory system to better manage pain levels, and instilling feelings of empowerment, self-confidence and dignity. The Arts in Medicine program offered a variety of therapeutic activities and events:
• Art therapy
• Artist-in-residence
• Catherine Chastain Open Art Studio
• Music therapy
• Music practitioners
• Art advisory council
• In-house performances by volunteer performers
• In-house exhibitions and shows
In 2019, the Patient Resource Center and Arts in Medicine program provided a wide variety of services to patients:
640 Behavioral health oncology visits provided by our psychologist
564 Hours of meetings provided by our 14 separate support groups
6,960 Inpatient visits provided by our trained music practitioners
1,150 Participants in our open art studio
1,018 Visits by our certified music therapists
267 Performances in common areas by our volunteer musicians
509 Inpatient visits by our certified art therapists
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT10
The Baylor Scott & White BMT Program made further strides in 2019 related to enhancements in immune effector cell treatments. After becoming the second site in Texas and first in North Texas to provide commercially approved CAR-T therapy for diffuse large B-cell lymphoma (DLBCL) in 2018, BMT physicians and hematologists on the Baylor University Medical Center medical staff actively utilized this novel therapy in the successful treatment of numerous patients. The program also continued to play a leadership role, in collaboration with Baylor Scott & White Research Institute and Texas Oncology, in research related to new immune effector cell therapies, several of which are scheduled for FDA review and potential approval in early 2020.
The Baylor Scott & White BMT Program also continued to evolve in terms of both structure and patient support. From a leadership perspective, Edward Agura, MD, resigned as the BMT medical director after almost 20 years of service. Luis Pineiro, MD, who previously served as the associate medical director for BMT, assumed the medical director role. He is supported by several assistant BMT medical directors, including Jana Reynolds, MD (quality/data); Carolina Escobar, MD (inpatient/outpatient nursing); and Medhat Askar, MD (cellular processing). The BMT team also hosted the annual BMT patient reunion, themed “Livin’ Texas Strong,” in which over 150 former transplant patients and their loved ones came together to rejoice about the many patients whose lives have been extended and transformed through transplant-related therapies.
BLOOD AND MARROW TRANSPLANT PROGRAM UPDATE
DEFENDERS The Texas Oncology blood and marrow transplant (BMT) physicians on the medical staff at Baylor University Medical Center (from L to R): Carolina Escobar, MD; Jana Reynolds, MD; Brian Berryman, MD; Luis Pineiro, MD; Nebu Koshy, MD
11
IMMUNOTHERAPY CONTINUES TO BE A PRIMARY RESEARCH FOCUS
Oncology clinical trials and research studies conducted through BSWRI by oncologists on the medical staff of Baylor Dallas continued to focus on novel immunotherapeutic strategies in 2019. Some of this research involved trials evaluating CAR-T cells and NK cells. In addition to these studies, oncologists on the medical staff of Baylor Dallas were principal investigators for trials evaluating new targets in triple negative breast cancer and a study evaluating the efficacy of an innovative approach for treating patients with non-Hodgkin lymphoma compared to the current standard of care.
Here’s a snapshot of these four trials from 2019:
FATE solid tumor: FATE-NK100 as monotherapy and in combination with monoclonal antibody in subjects with advanced solid tumors
The study is now closed to enrollment.
Principal investigator: Carlos Becerra, MD, medical director, Swim Across America Innovative Clinical Trials Center, Baylor Scott & White Charles A. Sammons Cancer Center
INNOVATIONS IN RESEARCH
CancerHatesPioneers.com
12
Study objective: This phase 1, single-dose, open-label, dose-escalation study was comprised of three regimens in an outpatient setting. Regimen A used FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. Regimen B used FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive advanced breast cancer, advanced gastric cancer or other advanced HER2+ solid tumors. Regimen C used FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer or head and neck squamous cell cancer or other epidermal growth factor receptor 1 positive advanced solid tumors.
“This study was a phase 1 trial in patients with solid tumors that have progressed on standard therapies. The study involved taking a subset of cells from a blood-related donor called natural killer cells and giving the cells to the patient with the hope that the cells would organize and attack the cancer. Investigators found that in normal individuals who had been previously exposed to a virus called CMV (cytomegalovirus) there is a subset of their natural killer cells that had antitumor properties. This was the subject of the study. We enrolled more than 30 patients, and there are some encouraging early signs that in fact the cells that are infused to patients had antitumor properties.”
– Carlos Becerra, MD
TRANSFORM: A study to compare the efficacy and safety of JCAR017 to standard of care in adult subjects with high-risk, transplant-eligible relapsed or refractory aggressive B-cell non-Hodgkin lymphomas
Principal investigator: Houston Holmes, MD
Study objective: This is a randomized, open-label, parallel-group, multi-center trial in adult subjects with relapsed or refractory aggressive non-Hodgkin lymphoma (NHL) to compare safety and efficacy between the standard of care strategy versus JCAR017 (lisocabtagene maraleucel or liso-cel). Subjects will be randomized to either receive standard of care or JCAR017.
“CAR T-cell therapies were first approved for treatment of lymphoma by the FDA in 2017, and research continues in an effort to make this approach more effective and more widely available. The standard approach to relapsed aggressive NHL has been high dose chemotherapy and autologous stem cell transplant. Approved CAR T-cell therapies now are available only after the patient has received two prior lines of therapy. Given the advances in CAR T-cell therapy, this study is comparing CAR T-cell therapy, specifically liso-cel, to autologous stem cell transplant. We know CAR T-cells can induce long-term remissions in patients for whom autologous transplant has failed, so the hope is that CAR therapies may be even more effective if given earlier in the course of therapy. Liso-cel is directed at CD19 (the same target on the lymphoma cells as currently approved CAR T-cells) but also is a unique preparation of two different types of T-cells, termed CD4+ and CD8+.
Patients with first relapse of aggressive NHL are randomized to treatment with either liso-cel or standard therapy including autologous transplant to compare the safety and efficacy of these approaches. We are very excited to be able to offer this trial to patients at Baylor Dallas and look forward to continued development of this important and advancing technology.”
– Houston Holmes, MD
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
13
Metabolomics: Pilot study to investigate targetable metabolic pathways sustaining triple negative breast cancer
Principal investigator: Joyce O’Shaughnessy, MD
Study objective: This study is designed to describe and discover new insights into the glucose, amino acid, and lipid metabolic dependencies of triple negative breast cancer (TNBC) via nuclear magnetic resonance spectroscopy analysis of in vivo glucose-labeled breast cancer biopsies.
“The primary objective of this study is to describe and discover new insights into the glucose, amino acid, and lipid metabolic dependencies of TNBC via nuclear magnetic resonance (NMR) spectroscopy analysis of in vivo [1,2-13C] glucose-labeled breast cancer biopsies. Tumor cells typically display an overall increase in glucose metabolism, associated with enhanced aerobic glycolysis and decreased oxidative phosphorylation, accompanied by a requirement for a high rate of protein, nucleotide and fatty acid synthesis to provide the raw materials for cell division. However, the metabolic dependencies of the various breast cancer subtypes are poorly understood. This study is not a treatment trial, but the hopes are to learn more about TNBC glucose metabolism and any clinical correlations that arise, based on the metabolomic profiles discovered.”
– Joyce O’Shaughnessy, MD
Treatment with oral LY3023414 (PI3K/mTOR inhibitor) to inhibit homologous recombination followed by prexasertib (ExIST)
Principal investigator: Joyce O’Shaughnessy, MD
Study objective: This study evaluates the efficacy of LY3023414 followed by prexasertib in patients with metastatic triple negative breast cancer (TNBC). The hypothesis of this trial is that administration of LY3023414 will inhibit non-homologous end joining (NHEJ) in metastatic TNBC, leading at the time of disease progression to metastases that are HR-deficient and sensitive to prexasertib therapy.
“The primary objective of this study is to assess the objective response rate (CR+PR) associated with oral LY3023414 followed by prexasertib in metastatic TNBC patients. Seventy to 80% of breast cancers have a basal gene expression profile, which is characterized by homologous recombination deficiency (HRD) and high proliferation. However, many metastatic triple negative breast cancers also have cells within the tumor that are proficient at repairing DNA. The LY3023414 agent will be given first to increase the DNA repair deficits within the metastatic triple negative breast cancer, thereby priming the TNBCs to respond deeply and durably to prexasertib, which is a DNA damaging cytotoxic agent. The objective of this trial is to reverse the intrinsic resistance within metastatic TNBC, thus augmenting the killing effects of the DNA damaging therapy.”
– Joyce O’Shaughnessy, MD
More information about oncology clinical trials and research studies being conducted at Baylor Dallas is available at BSWHealth.com/Research.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT14
OBSERVATIONAL STUDY OF SENTINEL LYMPH NODE BIOPSY IN PATIENT WITH MELANOMA: FALSE NEGATIVE SENTINEL LYMPH NODE RATE
MONITORING COMPLIANCE WITH EVIDENCE-BASED GUIDELINES
Portia Schmidt, MD; Jessica Kruger, MD; Ala Obaid, MS; Christine Landry, MD, FACS; Richard Vargas, BS, CCRC; Gerald Ogola, PhD; John T. Preskitt, MD, FACS
Background
Cutaneous melanoma is a significant health issue for the United States. There were over 87,110 newly diagnosed cases of invasive melanoma in 2017, and about 10,000 Americans are expected to die yearly from melanoma. One important factor for determining the risk of recurrence to the patient is the use of sentinel lymph node (SLN) biopsy for accurate lymph node staging. Less morbid than using lymph node dissection, SLN dissection allows for the assessment of the status of the lymph node1 with less risk for lymphedema than lymph node dissection.2 Thus, the single
most powerful predictor of the biological behavior of melanoma is the presence or absence of malignant cells in the SLN.
One issue with the use of SLN for staging in patients with melanoma is false positive results. Patients with melanoma can have a recurrence many years after the initial disease even in patients with a negative SLN.3 The factors associated with these false negative SLNs have been described in numerous studies. Age, presence of ulceration and tumor thickness have been associated with a higher incidence of falsely negative sentinel lymph nodes. However, this data has been inconsistent with one study showing greater tumor thickness being associated with a lower negative predictive value and greater false negative rate and another showing higher false negative rates associated with lower mean thickness. The calculated false negative sentinel lymph node biopsy rate in the Multicenter Selective Lymphadenectomy (MSLT) 1 trial has been estimated between 5 and 10%.4
Pilot study exploring use of fluorescent dye (indocyanine green) to optimize and reduce false negative rate. A: Primary melanoma injection site with 2.5 mg ICG using near infrared imaging. B: Transdermal visualization of dermal lymphatics. C: Sentinel node biopsy wound. D: Sentinel node with afferent lymphatic; confirmed with radiotracer.
A
B
B
C
D
A
C
PIONEER John T. Preskitt, MD
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
15
Materials and methods
An observational study was conducted on 110 melanoma patients who underwent an SLN biopsy at Baylor University Medical Center to look at the factors that contribute to false negative SLN diagnosis.
This cohort of 110 patients all had documented clinical follow up for at least 24 months. All patients had wide excision and sentinel node biopsy parameters according to the 2019 National Comprehensive Cancer Network (NCCN) Guidelines.5 Demographics and pathology reports were reviewed for each patient. Factors such as age, ulceration, tumor thickness, mitotic rate and tumor site were included in the analysis for each patient. Patients were sorted into three different groups based on their SLN biopsy results: false negative SLN, positive SLN and negative SLN. False negative SLN is defined as patients with a negative SLN who had a recurrence in the lymph node basin within two years. Whereas, positive and negative SLN are considered a true positive or negative SLN biopsy with no recurrence. False negative rate was calculated as [Number of false negatives/(number of false negatives + number of true positives)]. Negative predictive value was calculated as [Number of true negatives/(number of false negatives + number of true negatives)].
Data was analyzed using Microsoft Excel. Results were expressed as mean and percentage and compared across different groups.
Results
The study investigated 228 patients (mean age 65.1, 57% male) with 110 complete retrospective reviewed charts. A total of 36 patients were positive for malignant tumor cells in SLNs, 71 patients were negative for SLNs, and three patients had false negative SLNs results. The identification rate of true positive and true negative sentinel lymph node biopsies was 96.4%, and the identification rate of false negative sentinel lymph node biopsies was 7.7% (FN/FN+True Positive).
Primary melanoma locations included trunk (29%), head and neck (24%), and extremities (20% on arms and 15% on legs). Mean thickness and mitotic rate for all patients was 3.6 mm and 4.5 mitosis/mm2, respectively. An average of 4.9 sentinel lymph nodes were examined with a result of 0.7 sentinel lymph nodes positive.
In the true positive SLN group, the mean age above 50 was 68.9 years old, ulceration was not present in 66.7%, 97% had an intermediate thickness or greater (mean thickness 3.7 mm), mitoses present in 100%, and the main primary sites of melanoma were mostly hands and feet (26%), then trunk and arms (23% each).
In the true negative SLN group, the mean age above 50 was 68.9 years old, ulceration was not present (70.6%), mean thickness 2.3 mm (27.5% thin and 49% intermediate thickness), 87.2% with Clark level IV or higher, average mitotic rate 3.6 (4.8% with no identified mitosis and 95.2% with a mitotic index), and the main primary sites of melanoma were arms (29%), trunk (28%), head and neck (19%), and legs (19%).
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT16
Table 1: Comparison of characteristics between patients with false negative, positive and negative SLN biopsy.
Characteristics (4)
False negative SLN* N= 3
Positive SLN N= 36
Negative SLN N= 71
GenderMales 2 (66.7%) 20 (55.6%) 43 (60.6%)Females 1 (33.3%) 16 (44.4%) 28 (39.4%)Age<50 0 (0%) 7 (19.4%) 13 (18.3%)>50 3 (100%) 29 (80.6%) 58 (81.7%)UlcerationPresent 1 (33.3%) 10 (33.3%) 15 (29.4%)Not present 2 (66.7%) 20 (66.7%) 36 (70.6%)Thickness0-0.99 0 (0%) 1 (3.1%) 14 (27.5%)1-3.99 3 (100%) 23 (71.9%) 25 (49.0%)>4 0 (0%) 8 (25.0%) 12 (23.5%)Mitotic rate0 0 (0%) 0 (0%) 2 (4.8%)>0-7 3 (100%) 27 (93.1%) 32 (76.2%)>7 0 (0%) 2 (6.9%) 8 (19.0%)Clark levelII 0 (0%) 0 (0%) 3 (7.7%)III 1 (33.3%) 3 (14.3%) 2 (5.1%)IV 1 (33.3%) 12 (57.1%) 29 (74.4%)V 1 (33.3%) 6 (28.6%) 5 (12.8%)Site categoryHead and neck 3 (100%) 5 (14%) 13 (19%)Trunk 0 (0%) 8 (23%) 19 (28%)Arms 0 (0%) 8 (23%) 20 (29%)Leg 0 (0%) 5 (14%) 13 (19%)Hands and feet 0 (0%) 9 (26%) 2 (3%)Perineum 0 (0%) 0 (0%) 1 (1%)Lymphovascular invasionPresent 0 (0%) 5 (20.8%) 2 (4.1%)Not identified 3 (100%) 19 (79.2%) 47 (95.9%)Perineural invasionPresent 0 (0%) 3 (12.5%) 2 (4.8%)Not identified 2 (100%) 21 (87.5%) 40 (95.2%)
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
17
Of the false negative sentinel lymph node group, the mean age above 50 was 81.7 years old compared to true positive and true negative SLN group at 68.9 years old, ulceration was not present in 66.7%, the thickness was intermediate in 100% (mean thickness 2.4 mm), invasion into Clark level III or higher was present 100% of the time, and the main site for primary melanoma was head and neck (100% head and neck).
Conclusions
Although the total numbers are too small for statistical comparison, the data in these patients shows the false negative sentinel lymph node are more likely to be found in older patients (greater than 50 years old), higher Clark levels (Clark level III or greater), and in the head and neck regions. These factors increase occult nodal metastasis if the SLN result is falsely negative and provide misleading prognostic information. Following NCCN national guidelines for indications for sentinel lymph node biopsy, the false negative SLN rate at Sammons Cancer Center is in line with national guidelines.
Future studies should consider techniques to decrease the false negative rate with fluorescent dyes or a lower background count activity in the nodal basin, especially in patients who demonstrate melanoma features consistent with an increased rate of false negative SLN.
Summary
With a greater likelihood of falsely positive sentinel lymph node in patients with melanomas more deeply invasive, in older patients, and in head and neck melanomas, consideration should be given to measures to improve identification of sentinel lymph node, such as Spect images (CT with lymphoscintigraphy), higher clearance of background activity, and the addition of confirmatory fluorescent imaging.
1. Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol. 2011 Sep;104(4):379-85.
2. Roaten JB, Pearlman N, Gonzalez R, Gonzalez R, McCarter MD. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg. 2005 Jan;140(1):85-9.
3. Jones EL, Jones TS, Pearlman NW, et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg. 2013 May;148(5):456-61.
4. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005 Sep;242(3):302-11; discussion 11-3.
5. Coit DG, Thompson JA, Albertini MR, et al. Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 Apr 1;17(4):367-402.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT18
CREATING LIVING DRUGS IN THE MOST EXPERIENCED CGMP CELL MANUFACTURING FACILITY IN NORTH TEXAS
Cell therapy manufacturing at Baylor Dallas dates back to the late 1990s. At this time, cancer immunotherapy was in its infancy, and Baylor Dallas immunology researchers, including Karolina Palucka, MD, PhD; Joseph Fay, MD; and Jacques Banchereau, PhD, were exploring the potential for cellular vaccines in the fight against cancer. They were among the first scientists to begin studying the concept that dendritic cells, as master regulators of T-cell responses, could be harnessed to overcome immunotolerance and kill tumor cells. This idea would grow into a burgeoning new therapeutic field where today there are a number of
Food and Drug Administration (FDA)-approved cellular anticancer therapies, including two CAR-T drugs and many more, are being evaluated both in early- and late-stage clinical trials for a wide range of hematological and solid tumors.
Samples being removed or placed into vapor phase liquid nitrogen storage. Samples could be frozen PBMC (peripheral blood mononuclear cells) or another cellular component from blood or a finished cellular product.
PIONEER Jennifer Finholt, MS
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
19
This pioneering work at Baylor Dallas was done in collaboration with Ralph Steinman, PhD, of Rockefeller University, who would go on to win the Nobel Prize in 2011 for the discovery and functional characterization of dendritic cells. Given that resources for immunotherapy were limited, the investigators established an on-site laboratory for developing the dendritic cell vaccines for their early clinical trials. This laboratory would grow to become the Baylor Scott & White Research Institute (BSWRI) current good manufacturing practices (cGMP) cell manufacturing facility, a destination resource for research and development in cellular immunotherapies.
Their research focused on taking advantage of the fact that immature CD34+ dendritic cells are able to process and present antigens to the T cells. As described in their early work (Cancer Research, 2001), autologous CD34+ dendritic cell progenitors could be loaded ex vivo with melanoma antigens and delivered to patients with stage IV melanoma as a cellular vaccine. These dendritic cells would then prompt the patient’s immune system to target the melanoma antigens as invaders. The preliminary results were promising for safety and efficacy, especially in patients with limited disease.
By 2005, a larger clinical trial was underway to deliver antigen-primed immature dendritic cells as a cellular vaccine to patients with advanced melanoma. Other cellular vaccine therapy studies quickly followed, including a study combining dendritic cells with conventional chemotherapy for patients with stage IV melanoma and a study using dendritic cells loaded with HIV lipopeptides to treat HIV patients. Promising preliminary results for HIV have fueled interest in developing refined therapeutic approaches.
Also in 2005, the BSWRI cGMP cell manufacturing facility moved into its current home, an 1,800-square-foot FDA-regulated facility featuring 560 square feet of clean room space and additional support space for gowning, storage and freezers. The facility was designed to prevent cross-contamination and maximize cellular product consistency. The staff has over 25 collective years of cellular product manufacturing experience. According to Jennifer
Left: GMP manufacturing process in a biosafety level II cabinet in full sterile gowning. Right: Samples being incubated in a heated dry batch (metal beads instead of water).
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT20
Finholt, MS, manager of the BSWRI cGMP cell manufacturing facility, “The current facility was built so we would have the capacity to scale up and meet the needs of multiple concurrent clinical trials. We have gone from open processes to closed processes, which has improved efficiency while minimizing the risk of contamination.”
Starting in 2013, a clinical trial using dendritic cell vaccines for patients with triple-negative and ER+/HER2- breast cancer was established. This phase I/II trial, led by Joyce O’Shaughnessy, MD, assessed the safety and preliminary efficacy of a dendritic cell vaccine in combination with chemotherapy and surgery. Other recent trials include further development of dendritic cell vaccines for melanoma and a phase I trial evaluating dendritic cell vaccines in pancreatic cancer. In the last few years, over 200 patients have been treated with cellular vaccines generated by the BSWRI cGMP cell manufacturing facility.
Many phase I trials that rely on the resources provided by the BSWRI cGMP cell manufacturing facility are coordinated by the Swim Across America Innovative Clinical Trials Center (SAA-ICTC), a dedicated facility for early-stage clinical research at the Baylor Scott & White Sammons Cancer Center. The SAA-ICTC provides an integrated hub for patients to receive evaluation, treatment, laboratory tests and follow-up at a single site.
According to Gerard Zurawski, PhD, scientific director of the BSWRI cGMP cell manufacturing facility, “This is an exciting time in cell therapy. As we have seen with chimeric antigen receptor (CAR)-T cell therapy, the patients can have a very high response rate. Many variations on cellular therapies are in the works.”
GMP manufacturing step using a cell washer and concentrator with personnel in full sterile gowning.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
21
An in-house cell therapy manufacturing facility allows investigators to easily translate their preclinical research into phase I human trials. Furthermore, the robust manufacturing processes can support more advanced trials. The immune monitoring infrastructure at BSWRI, including the Flow Cytometry Core, Genomics Core and Luminex/Biotechnology Core, can offer additional in-house support services that are necessary for immunotherapy development and scale-up. The facility also offers regulatory support for the FDA investigational new drug (IND) process.
The BSWRI cGMP cell manufacturing facility boasts three class 10,000 (ISO 7) clean rooms in a restricted access facility. The clean rooms contain incubators, class 100 biological safety cabinets, centrifuges and elutriators. Sterile tube welders, an automated cell separator and an automated membrane filtration system are available for all projects, as are a variety of freezers (controlled rate -30°C, -80°C and liquid nitrogen). An automated Rees system provides environmental and equipment control monitoring.
According to Jaime Walkowiak, JD, senior vice president of research and chief operating officer of BSWRI, “The BSWRI cGMP cellular manufacturing facility has played a critical role in the development of immunotherapies for over two decades. It is now poised to meet the challenges of the complex array of new cellular therapies entering the clinical trials pipeline.”
The BSWRI cGMP cellular manufacturing facility is able to manufacture autologous and allogeneic cellular therapies and vaccines, including dendritic cells and natural killer cells. Transgenic cells, such CAR-T cells, can be generated in collaboration with a vector production resource.
Current studies supported by the BSWRI cGMP cell manufacturing facility include a multicenter trial whereby ex vivo-activated natural killer cells are harnessed to target solid tumors. According to Jaime Walkowiak, “This cGMP cell manufacturing facility offers a depth of experience that is unlike other research institutions in North Texas. We are ready to support the growing need for cellular therapeutics throughout the region and nationwide.”
Left: GMP manufacturing step, looking at the cells under a microscope with personnel in full sterile gowning. Right: Two quality control technicians working in a biosafety level II cabinet. Setting up a QC assay to test a cellular product manufactured in the GMP.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT22
Catrina Allen had her first mammogram at age 37. Her physician recommended starting routine breast screening earlier than the typical age of 40 because of Catrina’s dense breast tissue. The mammogram results were normal, and Catrina went about her daily routine. Part of that routine was a self-breast exam a few days a week. As a nurse, she knew the importance of checking her breasts regularly for any lumps or abnormalities.
COMMUNITY OUTREACH AND SUPPORT
WARRIORCatrina Allen, RN, genetics counseling patient
23
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
Just prior to the time for her second annual screening mammogram, Catrina noticed a small lump on her right breast during one of her self-exams. She says the lump, while not large or prominent, just felt different, so she immediately scheduled her mammogram. The imaging confirmed breast cancer. She was referred to an oncologist on the medical staff of Baylor University Medical Center. Further testing, including a bone scan, an echocardiogram and genetic testing, identified Catrina’s breast cancer as stage 1B, grade 3, invasive ductal carcinoma.
“When my oncologist referred me to the genetics counselor at Baylor Scott & White Sammons Cancer Center, at first I didn’t understand why. I had never heard that breast cancer could be a result of genetics. However, I knew that my paternal grandmother had experienced breast cancer in her 30s. As far as I know, there is no other history of cancer in my family. The genetic testing was simple, and I anxiously awaited the results.”
Catrina says the genetics counselor was “amazing.” “Even though the amount of information was overwhelming, the counselor broke it down and explained it to me in a way I could easily understand,” says Catrina. “The counselor reviewed all of my options as far as treatment and family
health history implications. My genetic tests came back positive, revealing I had the BRCA 2 breast cancer gene. I learned that I had probably inherited the gene from my paternal grandmother. The counselor suggested that my family members also have genetic testing performed and, unfortunately, the tests showed that I had passed the gene to my daughter.”
While devasting news at first, Catrina says genetic testing has been a positive experience overall. “I have all of the answers and that makes a world of difference,” explains Catrina. “My daughter is thinking about taking proactive measures, including surgery, to head off the possibility of developing breast cancer. It has also informed me and my oncologist about my best course of treatment. I just finished six cycles of chemotherapy, and I am scheduled for a double mastectomy in the near future. After I recover from the surgery, I will receive Herceptin immunotherapy, a proven treatment for early-stage breast cancer.”
Married with two children, Catrina, a Nebraska native who currently resides in Dallas, loves her work as a wound care nurse at Baylor Dallas. She also spends as much time with her 10-month-old grandchild as possible. When she has any spare time, Catrina enjoys drawing.
“ Even though the amount of information was overwhelming, the counselor broke it down and explained it to me in a way I could easily understand.” Catrina Allen, RN Genetics Counseling Patient
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT24
PATIENT NAVIGATION PROGRAM SEES SIGNIFICANT GROWTH
Since its founding, the Baylor Scott & White Patient Navigation Program has been guided by two over-arching goals—removing barriers to care and empowering patients to make informed medical decisions. From fiscal year 2018 to fiscal year 2019, the program experienced a 23% increase in patient volumes. In 2019, patient navigators identified 2,092 patient barriers to care and were able to effectively address 1,076. Interventions and referrals consisted of education by the patient navigator, American Cancer Society, on-site support services, child life services, chaplains, genetic counseling, and BEHOPE.
Also in 2019, patients with breast, colorectal and lung cancers comprised the top three tumor sites seen by patient navigators. Coming in a close fourth were hematology, endometrial, and head and neck cancers. Trained and certified patient navigators have years of experience assisting patients with specific needs pertaining to their cancer diagnosis. Patients who present with a higher acuity will also likely encounter more barriers during their cancer care. Patient navigators stay in close contact and provide ongoing support to patients and families throughout treatment and into survivorship.
Nurse and patient navigators continued to be an essential part of the complex cancer care delivery system. Navigators provided comprehensive and individualized support to 2,680 patients and their families through education, removal of barriers to care, emotional support, and referrals to services tailored to each individual patient’s circumstance and need.
To learn more about the Patient Navigation Program, call 214.820.3535, email [email protected] or visit BSWHealth.com/CancerSupport.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
25
A CONVERSATION WITH THIRD-YEAR ONCOLOGY FELLOW, PAMELA HOOF
Q: What led you to become a physician?
Dr. Hoof: I grew up in Memphis, the city of Elvis, BBQ, and blues and soul. I was a preemie and spent much of my early years in the neonatal intensive care unit and the hospital because I had severe asthma. I saw first-hand how the physicians and nurses helped patients get better, including me. From a child’s perspective, I decided I wanted to help people in the same way. In addition, my mom was an ICU nurse, and now she’s a home health nurse. So I think my career path was established from an early age.
ONCOLOGY EDUCATION
DEFENDERPamela Hoof, MD, third-year oncology fellow
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT26
Q: Why did you choose to pursue oncology?
Dr. Hoof: Unfortunately, I was exposed to cancer at a young age. My dad’s family, especially the women in his family, have a history of pancreatic cancer. Knowing their cancer experiences, I realized that oncology is an area of medicine that truly combines the most humanistic side of medicine with vast scientific innovation. I’ve always thought of cancer as the great unknown. Even with as many advances that we have in the field of oncology, there is still so much left to discover. So, I decided to take the plunge, accept the challenge and pursue the specialty.
Q: Why did you apply to the Baylor Dallas Oncology Fellowship Program?
Dr. Hoof: I did my medical training at Baylor Dallas, completing my residency here. A team of outstanding oncologists were my teachers, and I got to know the attending physicians very well. I couldn’t see myself completing my training anywhere else. I have to say I’ve not been disappointed with the decision I made.
Q: Knowing that there is never a “typical day,” what’s your day like as an oncology fellow?
Dr. Hoof: I’m a newlywed. My husband is an attorney, so our schedules are crazy. I wake up at 5:00 AM and take care of my dogs. I arrive at the hospital and attend tumor board that is held Tuesday through Friday. I also attend didactic lectures and conferences to augment my learning. Then, I begin seeing patients in the clinic with the attending physician with whom I am working. My day is always interesting, and I see a wide range of patients with a broad variety of cancers. I’m in clinic until at least 4:00 PM. When I get home, I read in the evenings, especially new journal articles. We also make sure we
have downtime, so we go to Zumba or kickboxing. I have pink boxing gloves. I also love testing recipes, and I love to bake. I also love to play tennis and to travel.
Q: What’s the best thing about being an oncology fellow?
Dr. Hoof: I love it here. We are fortunate to have an amazing group of attending physicians. The camaraderie is outstanding; it encourages you to be the best you can be. You can’t ask for anything better. I never hesitate to ask for other opinions. I also really like the variety of cases I see.
Q: What’s the most challenging thing about being an oncology fellow?
Dr. Hoof: Staying current. Keeping up with the latest and greatest information about oncology. It’s a great challenge to have.
Q: What are your plans after you finish the fellowship program?
Dr. Hoof: I’ve learned so much in the fellowship. My plans are to remain in the Dallas-Fort Worth area and to be a community oncologist.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
27
GROUNDBREAKING CEREMONY HELD FOR GENE AND JERRY JONES FAMILY HOPE LODGE
On May 7, 2019, Baylor Scott & White and the American Cancer Society (ACS) held a groundbreaking ceremony and major gift announcement for a Hope Lodge facility in Dallas. Located on property donated by Baylor Scott & White, adjacent to the Baylor University Medical Center campus, the 40,000-square-foot facility will provide more than 16,000 nights of free lodging annually for cancer patients and their families once it opens its doors in 2021.
In recognition of their lead gift, the facility will be named the Gene and Jerry Jones Family Hope Lodge. It will offer cancer patients and their caregivers a comfortable home away from home when they have to travel to receive care from any of North Texas’ premier medical centers.
“Through their decades of business and community investments, the Jones family has had a far-reaching impact in North Texas. Their support of Hope Lodge in Dallas will extend that reach and make a difference in the lives of those traveling to the region for their cancer care,” said Rowland K. Robinson, president of Baylor Scott & White Dallas Foundation. “Together with ACS and with the support of all our generous donors, Hope Lodge will soon be a reality for North Texas, and we are so grateful.”
PHILANTHROPY
Leaders at Baylor Scott & White and American Cancer Society celebrate the groundbreaking of the Hope Lodge with Gene and Jerry Jones. Pictured left to right: Rowland K. Robinson, Jim Hinton, Jerry Jones, Gene Jones, Jim Turner, Gary Reedy and Jeff Fehlis
28
The capital campaign for the facility has surpassed its original goal and has raised nearly $32 million to date. In addition to the Jones family, other major donors included the Don and Trudy Steen Charitable Foundation, Carmen and Jeff York, the Moody Foundation, the Horner family, the Mabee Foundation, and the Shapard family.
“This project, the first of its kind in North Texas, is a natural extension of our mission and deep commitment to patients,” said Jim Hinton, CEO, Baylor Scott & White Health. “The Gene and Jerry Jones Family Hope Lodge will be a haven for healing on patients’ journeys; its impact will be exponential, as it will not only help those fighting cancer but those fighting alongside them.”
For the thousands of cancer patients and their families who travel to North Texas each year for their care, the trip often means days, weeks or even months away from home. The combined emotional and financial toll of the loss of income, medical bills, hotel rooms and dining out can be staggering.
The Gene and Jerry Jones Family Hope Lodge will include 50 private guest suites, each with two beds and a private bathroom. In addition, the facility will feature common living areas, a dining room, laundry facilities, library, meditation room and outdoor garden. The American Cancer Society’s South Region headquarters also will be housed at this location in an adjacent facility.
“The American Cancer Society is committed to removing the emotional, physical and financial burdens that many cancer patients must face when they travel away from home for treatment,” said Jeff Fehlis, executive vice present for the American Cancer Society’s South Region. “Thanks to the generosity of partners and individuals who have stepped up to help with this project, we will soon be able to provide a home away from home for these patients, allowing them to focus on what’s important—getting well.”
The outdoor garden at American Cancer Society’s Hope Lodge will be a place for cancer patients and families to dine and relax.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
29
PATIENT PROFILES: JEFF YORK
To those looking at Jeff York at the podium speaking to attendees at the groundbreaking for Hope Lodge on the campus of Baylor University Medical Center, they saw an energetic, early 50s professional whose positive outlook on life guides his thoughts and actions. And that’s exactly what Jeff wanted them to see. During his remarks, he shared his personal cancer journey and how that experience made him a compassionate believer in the concept and invaluable service provided by Hope Lodge.
As chief sales officer and co-founder of Paycom, a publicly traded company that brings digital transformation to millions of American workers through technology for HR and payroll, Jeff has seen the peaks and valleys that accompany building a startup company. Through these challenges, he found mental management to be key to his success.
WARRIORJeff York, cancer patient and Hope Lodge donor
STORIES OF HOPE
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT30
At 48 years of age, Jeff began experiencing swallowing difficulties. Preliminary tests came back normal, but his primary care physician ordered an endoscopy. The test delivered a devastating diagnosis of stage IV gastroesophageal junction adenocarcinoma, a rare type of cancer of the esophagus that had spread from its original location. He immediately sought and received treatment in Houston, where he lived for months alone in an apartment close to the hospital, separated from his family. Over those months he endured intensive chemotherapy, radiation and a successful surgery. With one small tumor still evident, Jeff prepared for a second round of treatments, but his will to stay positive was severely tested when two months later 21 new tumors were detected.
Desperate to return to Dallas and to his family, he called his primary care physician seeking his advice. That’s how Jeff connected with his oncologist on the medical staff of Baylor Dallas and the Baylor Scott & White Sammons Cancer Center. His treatment plan was drastically altered with an eye on aggressively attacking his specific kind of cancer and the resulting recurrences. He received a mix of chemotherapy and a drug called Herceptin. At the end of treatment, Jeff received the incredible news that his cancer was virtually undetectable. Due to the nature of his cancer, he was told he would have to receive Herceptin infusions for the rest of his life. While disappointed with the news, Jeff resolved to make the best of his new lease on life.
“I started to reconcile thoughts of helping change the lives of other cancer patients with a dose of positivity based on the way I got through the whole original experience,” says Jeff. “I firmly believe that God values relationships more than anything. I think it’s why we were created—to have relationships with Him and one another.”
Jeff became a credentialed Baylor Scott & White volunteer. This helped him achieve his mission of bringing a positive light to everyone with whom he interacted, from the infusion rooms where he receives his treatment to waiting areas and office areas, uplifting patients and their families as well as honoring the passion and purpose of the dedicated oncology physicians.
When Jeff heard about Baylor Scott & White’s collaboration with the American Cancer Society to build a Hope Lodge on the Baylor Dallas campus, he knew it ticked all of his boxes. The beautifully appointed facility will provide free lodging to cancer patients and their families who live more than 40 miles from treatment. “I remember being in Houston alone, away from family, paying for lodging and not being able to talk to or socialize with others,” he says. “Thankfully, I had the financial means to be able to cover the costs of my out-of-town care. I met many people who, because they had to come from long distances for treatment, were on the brink of financial ruin. Hope Lodge takes the financial stress off patients’ shoulders. It also provides a warm, caring environment where patients and families can socialize and share their experiences and feelings with others that are going through the same thing.”
Jeff put his message of positivity into action with a multimillion-dollar gift to Hope Lodge. As a result, the Lodge’s dining hall will be named the Jeff and Carmen York Dining Hall. His chance for his personal ministry of helping others find a new home in Hope Lodge means the world to him. “It’s a gift,” Jeff said of Hope Lodge. “It’s a monumental move for thousands of people. It’s not about the money, it’s about what it does, and it’s about drawing people together. It’s about the hero’s journey that all of these patients and caregivers take.”
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
31
FIGHTERDenise Robertson, breast cancer patient
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT32
She had another CT scan, and it revealed that part of the tumor had attached itself to her liver. She was diagnosed with adrenal gland carcinoma cortex that affected the right upper part of her liver, so Denise had a liver biopsy. During the procedure, complications occurred, and she was immediately taken to Baylor University Medical Center to the transplant unit to stop internal bleeding and treatment. That’s when she met Carlos Becerra, MD. Dr. Becerra is an oncologist on the medical staff of Baylor Dallas and is the medical director of the Swim Across America Innovative Clinical Trials Center at Sammons Cancer Center.
During one of her visits, Denise noticed photos on his office wall from his days as an Olympic swimmer for Spain. “I asked him about learning how to swim and Swim Across America. That’s when Dr. Becerra became my ‘swimming instructor,’” says Denise. “He gave me lessons on how to navigate and fight this deadly disease. These lessons came in the form of swimming, which I then applied in my fight against cancer. Each lesson has taught me how to navigate from the deep waters of cancer back to the shore of life.
PATIENT PROFILES: DENISE ROBERTSONLearning to swim taught three-time cancer survivor how to face challenges, one stroke at a time
For Denise LaJean Robertson, life is full of surprises. Some have been pleasant and some have not. The 59-year-old three-time cancer survivor says one of her biggest surprises was learning how to swim. The challenge of being diagnosed with cancer again taught Denise to be disciplined and caused her to develop swimming techniques that helped her face and conquer her third and most serious bout with the disease.
Denise shared her personal cancer journey with participants in this year’s Dallas-Fort Worth Swim Across America event. (See page 33.) “My oncologist gave the event organizers my name. Words could not express the enthusiasm and how honored I was to be asked to give my testimony as a stem cell recipient,” says Denise. “Giving my testimony made me recall experiences of my faith being challenged to the core. It also made me realize that in life hearing certain words can cause you to turn around. That word came a third time for me—cancer.”
Denise’s cancer journey began in 2008 with a diagnosis of left breast cancer. She underwent chemotherapy and a left breast mastectomy. Then, in 2015 during a routine follow-up visit with her physician, a CT scan revealed a spot on her liver. She was diagnosis was adrenal gland carcinoma. In that same year, Denise had her adrenal gland removed.
In 2017, Denise went back to her oncologist because she was not feeling well.
FIGHTERDenise Robertson, breast cancer patient
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
33
Swim Across America Dallas event raises $270,000 for SAA Innovative Clinical Trials Center
A record number of more than 450 swimmers participated in the 2019 Dallas Swim Across America event on September 14 at Lake Ray Hubbard. More than $270,000 was raised to support the SAA Innovative Clinical Trials Center at Sammons Cancer Center. Since the first event in Dallas in 2011, SAA has raised $2.75 million. In addition to swimmers from Baylor Scott & White and other individuals, college teams from the University of North Texas, Texas Christian University and Southern Methodist University took to the water to raise much-needed dollars that will sponsor life-changing cancer research at Baylor Dallas.
More than $270,000 was raised to support the SAA Innovative Clinical Trials Center at Baylor Scott & White Sammons Cancer Center.
One lesson was a breathing exercise. Another was being able to make a stroke with each arm and complete a breath. Next, I learned to pull my arm straight down and make a circular motion. The last lesson was turning my head to the right, drawing a new breath through my mouth, and turning my head back while exhaling through my mouth or nose. In essence, every lesson I learned taught me perseverance.”
Denise says these life swim lessons have taught her to stand, to be courageous, to love and to be a fighter knowing there is hope. Her philosophy is Never Give Up! Live Your Life!
In September 2018, Denise became a stem cell recipient, receiving lifesaving stem cells from her youngest brother. “I am truly blessed by the Creator of Life. Since the day of my stem cell transplant, I haven’t received a chemo treatment. I’m coming up on one year since my transplant, and I am still being monitored, but at this point, the tumor has not grown,” says Denise.
A native of East Texas, Denise and her husband currently live in Ovilla, TX. She enjoys spending time with her four children and grandchildren, reading, bike riding, putting photos together, and swimming.
“My philosophy during my cancer journey has been to just fight and to live life most of all,” says Denise. “My awesome husband Vernon is a pastor, and we have been by each other’s side in this journey along with the ministry. Our ministry is built on the idea of Hold Your HOPE (Helping Other People Excel). HOPE gives me strength and has encouraged me to live my life. I’ve returned to college to finish my bachelor’s degree.”
CELEBRATING WOMEN LUNCHEON TURNS 20 WITH MORE THAN $35 MILLION RAISED.With keynote speaker Kristin Chenoweth
The annual Baylor Scott & White Dallas Foundation’s Celebrating Women Luncheon marked a milestone in 2019, celebrating its 20th anniversary year of raising money to support Baylor Scott & White’s fight against breast cancer in North Texas. Tom Thumb and Albertsons served as presenting sponsor for the 15th consecutive year.
Highlighting the luncheon were remarks from featured speaker, Kristin Chenoweth, Emmy and Tony award-winning actress and singer. Chenoweth says one of the most important uses of her celebrity voice is to support causes that are close to her heart, including the fight against breast cancer. Not only has she lost a loved one to the disease, she’s also been there as others close to her battled, including her mom, a two-time breast cancer survivor.
“I can tell you, from personal experience, show business is amazing, but it ain’t everything. I believe this is what matters,” said Chenoweth.
Since the first Celebrating Women event in 1999, more than $35 million has been raised. The 20th annual luncheon was held on October 11 at the Hilton Anatole and focused on the impact made in the lives of women and families fighting breast cancer in our community.
“We launched Celebrating Women 20 years ago because we believed there was a better answer for women fighting breast cancer,” said Baylor Scott & White Dallas Foundation president, Rowland K. Robinson. “Thanks to the generous support we have received from more than 12,000 donors over the last two decades, we have seen progress made in the way we are able to diagnose, treat and care for patients. However, we know the fight isn’t over and remain committed to improving the lives of those battling this disease now and in the future.”
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT34
BAYLOR SCOTT & WHITE DALLAS FOUNDATION RAISES $1.5 MILLION TO FUND TRIPLE NEGATIVE BREAST CANCER CLINICAL TRIAL
Triple negative breast cancer (TNBC) is one of the most aggressive forms of the disease. For patients battling TNBC, it can often feel like one step forward, two steps back, as they manage the setbacks and
recurrences that happen during their diagnosis and treatment. Joyce O’Shaughnessy, MD, a physician on the medical staff of Baylor Dallas and the holder of the Celebrating Women Chair in Breast Cancer Research, has worked tirelessly to help move the research and treatment options forward for these patients.
Based on Dr. O’Shaughnessy’s personal experience with one of her patients who had TNBC, a clinical trial was launched to evaluate the effectiveness of an FDA-approved drug for the treatment of multiple myeloma, bortezomib, in the treatment of TNBC patients. The trial was funded by $1.5 million raised by the Baylor Scott & White Dallas Foundation and conducted through Baylor Scott & White Research Institute.
Dr. O’Shaughnessy’s patient experienced six recurrences of TNBC, even though she had undergone five years of surgery, chemotherapy, radiation therapy, genomic sequencing and personalized treatment. The patient enrolled in a clinical trial for a new drug, BEZ 235. Although she initially responded to the medication, her breast cancer returned, and she discontinued
treatment in the trial. Dr. O’Shaughnessy began treating the patient with a new chemotherapy regimen. Her breast cancer had not previously responded to this type of treatment, but to their surprise, the patient experienced a “durable complete response” and has now been cancer free for more than five years.
Dr. O’Shaughnessy immediately began to ask, “What changed? Why was this patient, who previously had unsuccessful responses to chemotherapy, now an exceptional responder?” She hypothesized that BEZ 235 had not cured the patient’s cancer, but it had sensitized the cancer cells and made subsequent chemotherapy more effective. Because the BEZ 235 trial had closed, she set out to find a drug with similar mechanisms that would impact cancer cells in the same way. That’s when she came upon bortezomib.
The clinical trial involving bortezomib opened to patients who had received previous treatment with drugs already approved by the FDA for treatment breast cancer and other diseases. The trial tested whether the administration of bortezomib increases sensitivity of cancer cells and the effectiveness of the chemotherapy that follows. The unique factor of this trial is the order in which the FDA-approved drugs are given, targeting a specific hypothesis based on the clinical experience of Dr. O’Shaughnessy’s exceptional responder patient. The trial expands the options available to patients with metastatic disease, expedites the time for enrollment, and brings hope quickly to those in need.
PIONEER Joyce O’Shaughnessy, MD
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
35
Sammons Cancer Center
Performance Rate
Breast2016
ForwardDiagnosis Year 2016 (CoC) 2016* 2017** 2018**
BCS: Breast conservation surgery rate for women with AJCC clinical stage 0, I, or II breast cancer (Surveillance Measure)
NA 59.6% 65.7% 60.1% 67.2% 25.5% 28.9% 21.1%
NbX: Image or palpation-guided needle biopsy (core or FNA) is performed for the treatment of breast cancer (Quality Improvement Measure)
80.0% 91.2% 89.5% 91.0% 90.4% 92.8% 92.2% 94.1%
HT: Adjuvant Hormonal Therapy: Tamoxifen or third generation aromatase inhibitor is recommended or administered within 1 year (365 days) of diagnosis for women with AJCC T1cN0M0, or stage IB - III hormone receptor-positive breast cancer. (Accountability Measure)
90.0% 81.3% 91.5% 83.2% 91.7% 98.8% 97.7% 98.2%
MASTRT: Radiation therapy is considered or administered following any mastectomy within 1 year (365 days) of diagnosis for women with ≥ 4 positive lymph nodes (Accountability Measure)
90.0% 75.4% 86.2% 77.3% 85.8% 100.0% 100.0% 100.0%
BCRST: Post Breast Conserving Surgery Irradiation: Radiation therapy is administered within 1 year (365 days) of diagnosis for women under age 70 and receiving breast conserving surgery for breast cancer (Accountability Measure)
90.0% 82.5% 90.6% 85.2% 91.1% 93.1% 94.0% 91.0%
MAC (NQF #0559): Combination chemotherapy is recommended or administered within 4 months (120 days) of diagnosis for women under 70 with AJCC T1cN0M0, or stage IB - III hormone receptor negative breast cancer. (Accountability Measure)
NA 87.3% 92.5% 88.5% 92.7% 100.0% 96.0% 92.0%
Colon
ACT: Adjuvant Chemotherapy: Adjuvant chemotherapy is considered or administered within 4 months (120 days) of diagnosis to patients under age 80 with AJCC III (lymph node positive) colon cancer (Accountability Measure)
NA 80.0% 86.0% 81.6% 87.8% 91.7% 92.0% 91.0%
12 RLN: Surgical Resection Includes at Least 12 Lymph Nodes: At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Quality Improvement)
85.0% 93.3% 94.0% 92.6% 92.7% 96.6% 95.2% 90.7%
Rectum
RECRCT: Preoperative chemo and radiation are administered for clinical AJCC T3N0, T4N0, or Stage III; or postoperative chemo and radiation are administered within 180 days of diagnosis for clinical AJCC T1-2N0 with pathologic AJCC T3N0, T4N0, or Stage III; or treatment is considered; for patients under the age of 80 receiving resection for rectal cancer (Quality Improvement)
85.0% 83.0% 84.7% 85.4% 86.6% 91.3% 95.5% 93.4%
Gastric
G15RLN: At least 15 regional lymph nodes are removed and pathologically examined for resected gastric cancer (Quality Improvement)
80.0% 69.6% 71.1% 65.3% 64.7% 83.3% 88.9% 80.0%
Ovary
OVSAL: Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in Stages IIIIC Ovarian cancer (Surveillance Measure)
NA 58.9% 66.2% 60.8% 67.1% 59.3% 54.2% 53.3%
CANCER REGISTRY
NCDB Target
CoC State of Texas
Performance Rate
My CoC Program
Type (ACAD)
CoC Census Region
(West South Central)
Performance Rate
All CoC Programs
Performance Rate
Sammons Cancer Center
Performance Rate
Non-Small Cell Lung2016
ForwardDiagnosis Year 2016 (CoC) 2016* 2017** 2018**
10RLN: At least 10 regional lymph nodes are removed and pathologically examined for AJCC Stage 1A, 1B, IIA, and IIB resected NSCLC (Surveillance Measure)
NA 48.5% 50.0% 50.7% 49.0% 47.9% 58.1% 67.4%
LNoSurg: Surgery is not first course of treatment for cN2, M0 cases (Quality Improvement)
85.0% 92.8% 91.7% 93.5% 92.7% 100.0% 100.0% 100.0%
LCT: Systemic chemotherapy is considered or administered within 4 months to the day preoperatively or day of surgery to 6 months postoperatively or surgically resected cases with pathologic lymph node positive (pN1) and (pN2) NSCLC (Quality Improvement)
85.0% 81.7% 88.0% 84.2% 89.0% 100.0% 100.0% 100.0%
Cervix
CBRRT: Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer (Surveillance Measure)
NA 72.1% 71.3% 71.5% 69.4% NA NA NA
CERRT: Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer (Surveillance Measure)
NA 92.5% 89.1% 92.4% 88.9% NA NA NA
CERCT: Chemotherapy administered to cervical cancer patients who received radiation for Stages IB2-IV cancer (Group 1) or with positive pelvic nodes, positive surgical margin, and/or positive parametrium (Group 2) (Surveillance Measure)
NA 85.6% 83.0% 82.7% 81.2% NA NA NA
Endometrium
ENDLRC: Endoscopic, laparoscopic, or robotic performed for all endometrial cancer (excluding sarcoma and lymphoma), for all stages except Stage IV (Surveillance Measure)
NA 74.8% 77.9% 76.0% 80.0% 81.4% 87.0% 72.1%
ENDCTRT: Chemotherapy and/or radiation administered to patients with Stage IIIC or IV endometrial cancer (Surveillance Measure)
NA 75.0% 86.7% 76.5% 83.5% 80.0% 72.0% 71.0%
Bladder
BL2RLN: At least 2 lymph nodes are removed in patients under 80 undergoing partial or radical cystectomy (Surveillance Measure)
NA 93.6% 95.7% 93.5% 92.4% 100.0% 75.0% NA
BLCSTRI: Radical or partial cystectomy; or tri-modality therapy (local tumor destruction/excision with chemotherapy and radiation) for clinical T234N0M0 patients with urothelial carcinoma of the bladder, first treatment within 90 days of diagnosis (Surveillance Measure)
NA 43.1% 59.9% 49.0% 53.4% 54.5% NA NA
BLCT: Neo-adjuvant or adjuvant chemotherapy recommended or administered for patients with muscle invasive cancer undergoing radical cystectomy (Surveillance Measure)
NA 59.3% 65.7% 61.2% 66.7% 57.1% NA NA
Kidney
PD1RLN: At least 1 regional lymph node is removed and pathologically examined for primarily resected unilateral nephroblastoma (Surveillance Measure)
NA NA 85.6% NA 89.3% NA NA NA
*Data results released from the National Cancer Database as of 12/10/2019**Data in pending results by the Rapid Quality Reporting Process via the National Cancer Database
NCDB Target
CoC State of Texas
Performance Rate
My CoC Program
Type (ACAD)
CoC Census Region
(West South Central)
Performance Rate
All CoC Programs
Performance Rate
2019 PUBLICATIONS FROM SAMMONS CANCER CENTER
1. Abramson VG, Oliveira M, Cervantes A, Wildiers H, Patel MR, Bauer TM, Bedard PL, Becerra C, Richey S, Wei MC, Reyner E, Bond J, Cui N, Wilson TR, Moore HM, Saura C, Krop IE. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. Breast Cancer Res Treat. 2019 Nov;178(1):121-133.
2. Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O’Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J. Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase 2 KEYNOTE-086 Study. Ann Oncol. 2019 Mar 1;30(3):397-404.
3. Al-Temimi MH, Dyurgerova AM, Kidon M, Johna S. Feeding Jejunostomy Tube Placed during Esophagectomy: Is There an Effect on Postoperative Outcomes? Perm J. 2019;23.
4. Alsahhar JS, Idriss R, Bahirwani R. A Rare Case of Cutaneous Metastases Secondary to Hepatocellular Carcinoma. Clin Gastroenterol Hepatol 2019 Feb;17(3):e17.
5. Álvaro E, Cano JM, García JL, Brandáriz L, Olmedillas-López S, Arriba M, Rueda D, Rodríguez Y, Cañete Á, Arribas J, Inglada-Pérez L, Pérez J, Gómez C, García-Arranz M, García-Olmo D, Goel A, Urioste M, González-Sarmiento R, Perea J. Clinical and Molecular Comparative Study of Colorectal Cancer Based on Age-of-onset and Tumor Location: Two Main Criteria for Subclassifying Colorectal Cancer. Int J Mol Sci. 2019 Feb 22;20(4), 968.
6. Amin S, Findeis SK, Whiteley A, Krause JR. An unusual presentation of an uncommon lymphoma, hepatosplenic T-cell lymphoma. Proc (Bayl Univ Med Cent) 2019; 32(1): 129-130.
7. Antelo M, Golubicki M, Roca E, Mendez G, Carballido M, Iseas S, Cuatrecasas M, Moreira L, Sanchez A, Carballal S, Castells A, Boland CR, Goel A, Balaguer F. Lynch-like syndrome is as frequent as Lynch syndrome in early-onset non-familial non-polyposis colorectal cancer. Int J Cancer. 2019 Aug 1;145(3):705-713.
8. Arriba M, Sánchez C, Vivas A, Nutu OA, Rueda D, Tapial S, Rodríguez Y, Brandáriz L, García JL, García-Olmo D, Goel A, González-Sarmiento R, Urioste M, Perea J. Intermediate-onset colorectal cancer: A clinical and familial boundary between both early and late-onset colorectal cancer. PLoS One. 2019 May 16;14(5):e0216472.
9. Askar M, Sayer D, Wang T, Haagenson M, Spellman SR, Lee SJ, Madbouly A, Fleischhauer K, Hsu KC, Verneris MR, Thomas D, Zhang A, Sobecks RM, Majhail NS; CIBMTR® Immunobiology Working Committee. Analysis of Single Nucleotide Polymorphisms in the Gamma Block of the Major Histocompatibility Complex in Association with Clinical Outcomes of Hematopoietic Cell Transplantation: A CIBMTR Study. Biol Blood Marrow Transplant. 2019 Apr;25(4):664-672.
10. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of Liver Diseases in the World. J Hepatol. 2019 Jan;70(1):151-171
11. Ashktorab H, Delker D, Kanth P, Goel A, Carethers JM, Brim H. Molecular Characterization of sessile serrated adenoma/polyps from a large African American cohort. Gastroenterology. 2019 Aug;157(2):572-574.
12. Babar L, Kosovec JE, Jahangiri V, Chowdhury N, Zheng P, Omstead AN, Salvitti MS, Smith MA, Goel A, Kelly RJ, Jobe BA, Zaidi AH. Prognostic immune markers for recurrence and survival in locally advanced esophageal adenocarcinoma. Oncotarget. 2019 Jul 16;10(44):4546-4555.
13. Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, O’Shaughnessy J, Moroose RL, Santin AD, Abramson VG, Shah NC, Rugo HS, Goldenberg DM, Sweidan AM, Iannone R, Washkowitz S, Sharkey RM, Wegener WA, Kalinsky K. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2019 Feb 21;380(8):741-751.
14. Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O’Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI. Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. Eur Urol. 2019 Jun;75(6):929-937
15. Belmarez JA, Latifi HR, Zhang W, Matthews CM. Simultaneously occurring disseminated peritoneal leiomyomatosis and multiple extrauterine adenomyomas following hysterectomy. Proc (Bayl Univ Med Cent) 2019; 21(1): 126-128.
16. Bodei L, Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR. Time for a change and to adopt a novel molecular genomic approach in NETs. Nat Rev Clin Oncol. 2019 Apr;16(4):269-270.
17. Buhrmann C, Yazdi M, Popper B, Shayan P, Goel A, Aggarwal BB, Shakibaei M. Evidence that TNF-β induces proliferation in colorectal cancer cells and resveratrol can down-modulate it. Exp Biol Med (Maywood). 2019 Jan;244(1):1-12
18. Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738.
18. Clifford M, Bannon S, Bednar EM, Czerwinski J, Davis J, Dunnington L, Shahrukh Hashmi S, DiNardo CD. Clinical applicability of proposed algorithm for identifying individuals at risk for hereditary hematologic malignancies. Leuk Lymphoma. 2019 Jul 5:1-8.
19. Cobleigh M, Yardley D, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Hurvitz SA, O’Shaughnessy J, Mason G, Antao V, Li H, Chu L, Jahanzeb M. Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status From SystHERs. Clin Cancer Res. 2019 Nov 26. pii: clincanres.2350.2019. doi: 10.1158/1078-0432.CCR-19-2350. [Epub ahead of print]
20. Conrad C, Fleshman JW Jr. Minimally Invasive Oncologic Surgery, Part I. Surg Oncol Clin N Am. 2019 Jan;28(1):xv-xvii.
21. Conrad C, Fleshman JW Jr. Minimally Invasive Oncologic Surgery, Part II. Surg Oncol Clin N Am. 2019 Apr;28(2):xv-xvii.
22. Cortes J, Calvo V, Ramírez-Merino N, O’Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J., Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Ann Oncol. 2019 Jul 1;30(7):1179.
23. Coyle YM, Ogola GO, MacLachlan CR, Hinshelwood MM, Fleming NS. Acute care model that reduces oncology-related unplanned hospitalizations to promote quality of care and reduce cost. J Cancer Policy. 2019; 21:100193.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT38
24. Crow LD, Jambusaria-Pahlajani A, Chung CL, Baran DA, Lowenstein SE, Abdelmalek M, Ahmed RL, Anadkat MJ, Arcasoy SM, Berg D, Bibee KP, Billingsley E, Black WH, Blalock TW, Bleicher M, Brennan DC, Brodland DG, Brown MR, Carroll BT, Carucci JA, Chang TW, Chaux G, Cusack CA, Dilling DF, Doyle A, Emtiazjoo AM, Ferguson NH, Fosko SW, Fox MC, Goral S, Gray AL, Griffin JR, Hachem RR, Hall SA, Hanlon AM, Hayes D Jr, Hickey GW, Holtz J, Hopkins RS, Hu J, Huang CC, Jiang SIB, Kapnadak SG, Kraus ES, Lease ED, Leca N, Lee JC, Leitenberger JJ, Lim MA, Longo MI, Malik SM, Mallea JM, Menter A, Myers SA, Neuburg M, Nijhawan RI, Norman DJ, Otley CC, Paek SY, Parulekar AD, Patel MJ, Patel VA, Patton TJ, Pugliano-Mauro M, Ranganna K, Ravichandran AK, Redenius R, Roll GR, Samieo’shaughnes FH, Shin T, Singer JP, Singh P, Soon SL, Soriano T, Squires R, Stasko T, Stein JA, Taler SJ, Terrault NA, Thomas CP, Tokman S, Tomic R, Twigg AR, Wigger MA, Zeitouni NC, Arron ST. Initial Skin Cancer Screening for Solid Organ Transplant Recipients in the United States: Delphi Method Development of Expert Consensus Guidelines. Transpl Int. 2019 Dec;32(12):1268-1276.
25. DiNorcia J, Florman SS, Haydel B, Tabrizian P, Ruiz RM, Klintmalm GB, Senguttuvan S, Lee DD, Taner CB, Verna EC, Halazun KJ, Hoteit M, Levine MH, Chapman WC, Vachharajani N, Aucejo F, Nguyen MH, Melcher ML, Tevar AD, Humar A, Mobley C, Ghobrial M, Nydam TL, Amundsen B, Markmann JF, Berumen J, Hemming AW, Langnas AN, Carney CA, Sudan DL, Hong JC, Kim J, Zimmerman MA, Rana A, Kueht ML, Jones CM, Fishbein TM, Markovic D, Busuttil RW, Agopian VG. Pathologic Response to Pretransplant Locoregional Therapy is Predictive of Patient Outcome After Liver Transplantation for Hepatocellular Carcinoma: Analysis From the US Multicenter HCC Transplant Consortium. Ann Surg. 2019 Mar 5. doi: 10.1097/SLA.0000000000003253. [Epub ahead of print]
26. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group (Berryman R). Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2019 Jan 19;393(10168):253-264.
27. Ding L, Su Y, Fassl A, Hinohara K, Qiu X, Harper NW, Huh SJ, Bloushtain-Qimron N, Jovanović B, Ekram M, Zi X, Hines WC, Alečković M, Gil Del Alcazar C, Caulfield RJ, Bonal DM, Nguyen QD, Merino VF, Choudhury S, Ethington G, Panos L, Grant M, Herlihy W, Au A, Rosson GD, Argani P, Richardson AL, Dillon D, Allred DC, Babski K, Kim EMH, McDonnell CH 3rd, Wagner J, Rowberry R, Bobolis K, Kleer CG, Hwang ES, Blum JL, Cristea S, Sicinski P, Fan R, Long HW, Sukumar S, Yeon Park S, Garber JE, Bissell M, Yao J, Polyak K. Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. Nat Commun. 2019 Sep 13;10(1):4182.
28. Ear J, Dunkel Y, Mittal Y, Lim BBC, Liu L, Holda MK, Nitsche U, Barbazán J, Goel A, Janssen KP, Aznar N, Ghosh P. Two Isoforms of the Guanine Nucleotide Exchange Factor, Daple/CCDC88C Cooperate as Tumor Suppressors. Sci Rep. 2019 Aug 20;9(1):12124.
29. Ebrahim A, Kondapalli N, Webster WS. Radical cystoprostatectomy to treat urachal carcinoma. Proc (Bayl Univ Med Cent). 2019;32(4):571-581.
30. Elmets CA, Leonardi CL, Davis DMR, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kivelevitch D, Kiselica M, Korman NJ, Kroshinsky D, Lebwohl M, Lim HW, Paller AS, Parra SL, Pathy AL, Prater EF, Rupani R, Siegel M, Stoff B, Strober BE, Wong EB, Wu JJ, Hariharan V, Menter A. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019 Apr;80(4):1073-1113.
31. Feng MP, Baucom RB, Broman KK, Harris DA, Holzman MD, Huang LC, Kaiser JL, Kavalukas SL, Oyefule OO, Phillips SE, Poulose BK, Pierce RA. Early repair of ventral incisional hernia may improve quality of life after surgery for abdominal malignancy: a prospective observational cohort study. Hernia. 2019 Feb;23(1):81-90.
32. Feng Z, Marrero JA, Khaderi S, Singal AG, Kanwal F, Loo N, Beretta L, Ning J, El-Serag HB. Design of the Texas Hepatocellular Carcinoma Consortium Cohort Study. Am J Gastroenterol. 2019 Mar;114(3):530-532.
33. Findeis SK, Salicru MN, Agarwal A. Myxoma versus myxoid liposarcoma involving the kidneys. Proc (Bayl Univ Med Cent). 2019;32(3):402-404.
34. Finlay E, Newport K, Sivendran S, Kilpatrick L, Owens M, Buss MK. Models of Outpatient Palliative Care Clinics for Patients With Cancer. J Oncol Pract. 2019 Apr;15(4):187-193.
35. Fleshman J, Branda ME, Sargent DJ, Boller AM, George VV, Abbas MA, Peters WR Jr, Maun DC, Chang GJ, Herline A, Fichera A, Mutch MG, Wexner SD, Whiteford MH, Marks J, Birnbaum E, Margolin DA, Larson DW, Marcello PW, Posner MC, Read TE, Monson JRT, Wren SM, Pisters PWT, Nelson H. Disease-free Survival and Local Recurrence for Laparoscopic Resection Compared With Open Resection of Stage II to III Rectal Cancer: Follow-up Results of the ACOSOG Z6051 Randomized Controlled Trial. Ann Surg. 2019 Apr;269(4):589-595.
36. Forero-Torres A, Ramchandren R, Yacoub A, Wertheim MS, Edenfield WJ, Caimi P, Gutierrez M, Akard L, Escobar C, Call J, Persky D, Iyer S, DeMarini DJ, Zhou L, Chen X, Dawkins F, Phillips TJ. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019 Apr 18;133(16):1742-1752.
37. Formisano L, Lu Y, Servetto A, Hanker AB, Jansen VM, Bauer JA, Sudhan DR, Guerrero-Zotano AL, Croessmann S, Guo Y, Ericsson PG, Lee KM, Nixon MJ, Schwarz LJ, Sanders ME, Dugger TC, Cruz MR, Behdad A, Cristofanilli M, Bardia A, O’Shaughnessy J, Nagy RJ, Lanman RB, Solovieff N, He W, Miller M, Su F, Shyr Y, Mayer IA, Balko JM, Arteaga CL. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019 Mar 26;10(1):1373.
38. Fuji T, Umeda Y, Nyuya A, Taniguchi F, Kawai T, Yasui K, Toshima T, Yoshida K, Fujiwara T, Goel A, Nagasaka T. Detection of Circulating MicroRNAs with Ago2 Complexes to Monitor the Tumor Dynamics of Colorectal Cancer Patients during Chemotherapy. Int J Cancer. 2019 May 1;144(9):2169-2180.
39. Garbarino GM, Marchese U, Tobome R, Ward MA, Vibert E, Gayet B, Cherqui D, Fuks D. Laparoscopic versus open unisegmentectomy in two specialized centers. Feasibility and short-term results. HPB (Oxford). 2019 Oct 28. pii: S1365-182X(19)30729-4. doi: 10.1016/j.hpb.2019.09.017. [Epub ahead of print]
40. Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS, Spigel DR, Jeong W, Scaglioni PP, Zhang S, Li M, Weaver DT, Vaikus L, Keegan M, Horobin JC, Burns TF. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer. 2019 Nov 4;139:60-67.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
39
2019 PUBLICATIONS FROM SAMMONS CANCER CENTER
41. Gregston AP, Metter DM, Osborne CRC, Pippen Jr J. Giant malignant phyllodes tumor with metastasis to the brain. Proc (Bayl Univ Med Cent). 2019 32(1):116-118.
42. Grünwald V, Powles T, Choueiri TK, Hutson TE, Porta C, Eto M, Sternberg CN, Rha SY, He CS, Dutcus CE, Smith A, Dutta L, Mody K, Motzer RJ. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Future Oncol. 2019 Mar;15(9):929-941.
43. Haider AS, Sumdani H, McCaslin J, Habib A, Layton KF. Aggressive Endovascular Management of Massive Dural Venous Sinus Thrombosis in the Setting of Acute Myeloid Leukemia. Cureus. 2019 Jan 15;11(1):e3891.
44. Hamid O, Cowey CL, Offner M, Faries M, Carvajal RD. Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. Cancers (Basel). 2019 Oct 24;11(11).
45. Hoang JT, Weissenborn MR, Spigel JJ, Welch BJ, Grossman SJ. I-131 uptake in the breast from fat necrosis. Proc (Bayl Univ Med Cent). 2019; 32(1):140-142.
46. Hoang JT, Yang R, Shah ZA, Spigel JJ, Pippen JE. Clinico-radiologic features and management of hematological tumors in the breast: a case series. Breast Cancer. 2019 Mar;26(2):244-248.
47. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O’Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2019 Nov 1;30(11):1842.
48. Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, Chinnaiyan P, Wan L, Marcus S, Campian JL. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol. 2019 May;142(3):537-544.
49. Hurvitz SA, Gonçalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2019 Nov 25. pii: theoncologist.2019-0493. doi: 10.1634/theoncologist.2019-0493. [Epub ahead of print]
50. Hurvitz SA, O’Shaughnessy J, Mason G, Yardley D, Jahanzeb M, Brufsky AM, Rugo HS, Swain SM, Kaufman PA, Tripathy D, Chu L, Li H, Antao V, Cobleigh M. Central Nervous System Metastasis in Patients With HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival From SystHERs. Clin Cancer Res. 2019 Apr 15;25(8):2433-2441.
51. Huskic A, Goldstein R. Radiofrequency ablation of isolated liver metastasis from facial Merkel cell carcinoma. Proc (Bayl Univ Med Cent). 2019;31(4):522-523.
52. Izumi D, Toden S, Ureta E, Ishimoto T, Baba H, Goel A. TIAM1 promotes chemoresistance and tumor invasiveness in colorectal cancer. Cell Death Dis. 2019 Mar 19;10(4):267.
53. Izumi D, Gao F, Toden S, Sonohara F, Kanda M, Ishimoto T, Kodera Y, Wang X, Baba H, Goel A. A genome wide transcriptomic approach identifies a novel gene expression signature for the detection of lymph node metastasis in patients with early stage gastric cancer. EBioMedicine. 2019 Mar;41:268-275
54. Jackson DN, Theiss AL. Gut bacteria signaling to mitochondria in intestinal inflammation and cancer. Gut Microbes. 2019 Mar 26:1-20.
55. Jansen AML, Ghosh P, Dakal TC, Slavin TP, Boland CR, Goel A. Novel candidates in early-onset familial colorectal cancer. Fam Cancer. 2019 Sep 25. doi: 10.1007/s10689-019-00145-5. [Epub ahead of print]
56. Jones VE, McIntyre KJ, Paul D, Wilks ST, Ondreyco SM, Sedlacek S, Melnyk A, Oommen SP, Wang Y, Peck SR, O’Shaughnessy JA. Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study. Oncologist. 2019 Sep;24(9):1153-1158.
57. Kandimalla R, Ozawa T, Gao F, Wang X, Goel A; T1 Colorectal Cancer Study Group. Gene Expression Signature in Surgical Tissues and Endoscopic Biopsies Identifies High-risk T1 Colorectal Cancers. Gastroenterology. 2019 Jun;156(8):2338-2341
58. Kandimalla R, Gao F, Li Y, Huang H, Ke J, Deng X, Zhao L, Zhou S, Goel A, Wang X. RNAMethyPro: a biologically conserved signature of N6-methyladenosine regulators for predicting survival at pan-cancer level. NPJ Precis Oncol. 2019 May 1;3:13.
59. Kanwal F, Tapper EB, Ho C, Asrani SK, Ovchinsky N, Poterucha J, Flores A, Ankoma-Sey V, Lun B, Volk M. Development of Quality Measures in Cirrhosis by the Practice Metrics
Committee of the American Association for the Study of Liver Diseases. Hepatology. 2019 Apr;69(4):1787-1797
60. Kelly RJ, Ansari AM, Miyashita T, Zahurak M, Lay F, Ahmed AK, Born LF, Pezhouh MK, Salimain KJ, Ng C, Matsangos AE, Stricker-Krongrad A-H, Mukaisho K-I, Marti GP, Chung CH, Canto MI, Rudek MA, Meltzer SJ, Harmon JW. Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett’s Esophagus to Invasive Esophageal Adenocarcinoma. Ann Surgery 2019 Jul 8. doi: 10.1097/SLA.0000000000003455. [Epub ahead of print]
61. Kelly RJ, Shepherd FA, Krivoshik A, Jie F, Horn L. A Phase 3, Randomized, Open-label Study of ASP8273 Versus Erlotinib or Gefitinib in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer. Ann Oncol. 2019 Jul 1;30(7):1127-1133.
62. Kelly RJ, Turner R, Chen YW, Rigas JR, Fernandes AW, Karve S. Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States. J Oncol Pract. 2019 Aug;15(8):e717-e727.
63. Kelly RJ. The emerging role of immunotherapy for esophageal cancer. Curr Opin Gastroenterol. 2019 Apr 30. doi: 10.1097/MOG.0000000000000542. [Epub ahead of print]
64. Kelly RJ. Emerging Multimodality Approaches to Treat Localized Esophageal Cancer. J Natl Compr Canc Netw. 2019 Aug 1;17(8):1009-1014.
65. Khwaja R, Mantilla E, Fink K, Pan E. Adult Primary Peripheral PNET/Ewing’s Sarcoma of the Cervical and Thoracic Spine. Anticancer Res. 2019 Aug;39(8):4463-4465.
66. Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 Aug 15;25(16):5143-5155.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT40
67. Konda VJA, Souza RF. Barrett’s Esophagus and Esophageal Carcinoma: Can Biomarkers Guide Clinical Practice? Curr Gastroenterol Rep. 2019 Mar 12;21(4):14.
68. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019 Oct 17;381(16):1535-1546.
69. Le DK, Agarwal A. Intraductal papillary neoplasm of the bile duct. Proc (Bayl Univ Med Cent) 2019;32(1):124-125.
70. Lennon KM, Wakefield DL, Maddox AL, Brehove MS, Willner AN, Garcia-Mansfield K, Meechoovet B, Reiman R, Hutchins E, Miller MM, Goel A, Pirrotte P, Van Keuren-Jensen K, Jovanovic-Talisman T. Single molecule characterization of individual extracellular vesicles from pancreatic cancer. J Extracell Vesicles. 2019 Nov 4;8(1):1685634.
71. Lieb S, Blaha-Ostermann S, Kamper E, Rippka J, Schwarz C, Ehrenhöfer-Wölfer K, Schlattl A, Wernitznig A, Lipp JJ, Nagasaka K, van der Lelij P, Bader G, Koi M, Goel A, Neumüller RA, Peters JM, Kraut N, Pearson MA, Petronczki M, Wöhrle S. Werner syndrome helicase is a selective vulnerability of microsatellite instability-high tumor cells. Elife. 2019 Mar 25;8.
72. Liu E, Paulson S, Gulati A, Freudman J, Grosh W, Kafer S, Wickremesinghe PC, Salem RR, Bodei L. Assessment of NETest Clinical Utility in a U.S. Registry-Based Study. Oncologist. 2019 Jun;24(6):783-790.
73. Maker AV, Tran TB, Coburn N, Fong ZV, Cardona K, Newell P, Morris-Stiff G, Chavin K, Mansour J; members of the AHPBA Research Committee Consensus Conference (Celinski, S). Does attending a Delphi consensus conference impact surgeon attitudes? Survey results from the Americas HepatoPancreatoBiliary Association consensus conference on small asymptomatic pancreatic neuroendocrine tumors. HPB (Oxford). 2019 May;21(5):524-530.
74. Mansour JC, Chavin K, Morris-Stiff G, Warner SG, Cardona K, Fong ZV, Maker A, Libutti SK, Warren R, St Hill C, Celinski S, Newell P, Ly QP, Howe J, Coburn N. Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association. HPB (Oxford). 2019 May;21(5):515-523.
75. Matsuyama T, Ishikawa T, Takahashi N, Yamada Y, Yasuno M, Kawano T, Uetake H, Goel A. Transcriptomic expression profiling identifies ITGBL1, an epithelial to mesenchymal transition (EMT)-associated gene, is a promising recurrence prediction biomarker in colorectal cancer. Mol Cancer. 2019 Feb 4;18(1):19.
76. Mehta RS, Holtan SG, Wang T, Hemmer MT, Spellman SR, Arora M, Couriel DR, Alousi AM, Pidala J, Abdel-Azim H, Ahmed I, Aljurf M, Askar M, Auletta JJ, Bhatt V, Bredeson C, Chhabra S, Gadalla S, Gajewski J, Gale RP, Gergis U, Hematti P, Hildebrandt GC, Inamoto Y, Kitko C, Khandelwal P, MacMillan ML, Majhail N, Marks DI, Mehta P, Nishihori T, Olsson RF, Pawarode A, Diaz MA, Prestidge T, Qayed M, Rangarajan H, Ringden O, Saad A, Savani BN, Seo S, Shah A, Shah N, Schultz KR, Solh M, Spitzer T, Szer J, Teshima T, Verdonck LF, Williams KM, Wirk B, Wagner J, Yared JA, Weisdorf DJ. GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. Blood Adv. 2019 May 14;3(9):1441-1449.
77. Menyhart O, Kakisaka T, Pongor LS, Uetake H, Goel A, Győrffy B. Uncovering Potential Therapeutic Targets in Colorectal Cancer by Deciphering Mutational Status and Expression of Druggable Oncogenes. Cancers (Basel). 2019 Jul 14;11(7).
78. Nadler E, Joo S, Boyd M, Black-Shinn J, Chirovsky D. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Future Oncol. 2019 Mar;15(7):739-751.
79. Navas MC, Glaser S, Dhruv H, Celinski S, Alpini G, Meng F. Hepatitis C virus infection and cholangiocarcinoma: An insight into epidemiological evidences and hypothetical mechanisms of oncogenesis. Am J Pathol. 2019 Jun;189(6):1122-1132.
80. Nehme F, Rowe K, Palko W, Tofteland N, Salyers W. Autoimmune metaplastic atrophic gastritis and association with neuroendocrine tumors of the stomach. Clin J Gastroenterol. 2019 Nov 28. doi: 10.1007/s12328-019-01074-7. [Epub ahead of print]
81. O’Shaughnessy J, Kaklamani V, Kalinsky K. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. Future Oncol. 2019 May;15(14):1641-1653.
82. Okugawa Y, Toiyama Y, Hur K, Yamamoto A, Yin C, Ide S, Kitajima T, Fujikawa H, Yasuda H, Koike Y, Okita Y, Hiro J, Yoshiyama S, Araki T, Miki C, McMillan DC, Goel A, Kusunoki M. Circulating miR-203 derived from metastatic tissues promotes myopenia in colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):536-548.
83. Okugawa Y, Toiyama Y, Yamamoto A, Shigemori T, Ide S, Kitajima T, Fujikawa H, Yasuda H, Hiro J, Yoshiyama S, Yokoe T, Saigusa S, Tanaka K, Shirai Y, Kobayashi M, Ohi M, Araki T, McMillan DC, Miki C, Goel A, Kusunoki M. Lymphocyte-C-reactive Protein Ratio as Promising New Marker for Predicting Surgical and Oncological Outcomes in Colorectal Cancer. Ann Surg. 2019 Feb 16. doi: 10.1097/SLA.0000000000003239. [Epub ahead of print]
84. Ott PA, Pavlick AC, Johnson DB, Hart LL, Infante JR, Luke JJ, Lutzky J, Rothschild NE, Spitler LE, Cowey CL, Alizadeh AR, Salama AK, He Y, Hawthorne TR, Bagley RG, Zhang J, Turner CD, Hamid O. A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma. Cancer. 2019 Apr 1;125(7):1113-1123.
85. Panezai MA, Owen C, Szerlip HM. Partial Fanconi syndrome induced by ifosfamide. Proc (Bayl Univ Med Cent). 2019; 32(1):73-74.
86. Papaconstantinou HT, Birnbaum EH, Ricciardi R, Margolin DA, Moesinger RC, Lichliter WE, Thomas JS, Bergamaschi R. Impact of a Novel Surgical Wound Protection Device on Observed versus Expected Surgical Site Infection Rates after Colectomy Using the National Surgical Quality Improvement Program Risk Calculator. Surg Infect (Larchmt). 2019 Jan;20(1):35-38.
87. Patel SS, Rybicki LA, Yurch M, Thomas D, Liu H, Dean R, Jagadeesh D, Hill B, Pohlman B, Bolwell B, Hanna R, Hamilton BK, Kalaycio M, Gerds AT, Cober E, Mossad S, Zhang A, Majhail NS, Askar M, Sobecks R. Influence of major histocompatibility complex class I chain-related gene a polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2019 Dec 24. pii: S1658-3876(19)30104-9. doi: 10.1016/j.hemonc.2019.10.001. [Epub ahead of print]
88. Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O’Shaughnessy JA. Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer. Breast J. 2019 Sep;25(5):880-888.
89. Paul D, Vukelja SJ, Ann Holmes F, Blum JL, McIntyre KJ, Lindquist DL, Osborne CR, Sanchez IJ, Goldschmidt JH, Wang Y, Asmar L, Strauss L, O’Shaughnessy J. Randomized phase-II evaluation of letrozole plus dasatinib in hormone receptor positive metastatic breast cancer patients. NPJ Breast Cancer. 2019 Oct 28;5:36.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
41
2019 PUBLICATIONS FROM SAMMONS CANCER CENTER
90. Perea J, García JL, Corchete L, Lumbreras E, Arriba M, Rueda D, Tapial S, Pérez J, Vieiro V, Rodríguez Y, Brandáriz L, García-Arranz M, García-Olmo D, Goel A, Urioste M, González Sarmiento R. Redefining synchronous colorectal cancers based on tumor clonality. Int J Cancer. 2019 Apr 1;144(7):1596-1608.
91. Peters WR. What Every Colorectal Surgeon Should Know About the New American Cancer Society’s Colorectal Cancer Screening Guidelines. Dis Colon Rectum. 2019 Apr;62(4):397-398.
92. Peters Y, Al-Kaabi A, Shaheen NJ, Chak A, Blum A, Souza RF, Di Pietro M, Iyer PG, Pech O, Fitzgerald RC, Siersema PD. Barrett oesophagus. Nat Rev Dis Primers. 2019 May 23;5(1):35.
93. Plichta JK, Sebastian ML, Smith LA, Menendez CS, Johnson AT, Bays SM, Euhus DM, Clifford EJ, Jalali M, Kurtzman SH, Taylor WA, Hughes KS. Germline Genetic Testing: What the Breast Surgeon Needs to Know. Ann Surg Oncol. 2019 Jul;26(7):2184-2190.
94. Puri V, Gaissert HA, Wormuth DW, Grogan EL, Burfeind WR, Chang AC, Seder CW, Fernandez FG, Brown L, Magee MJ, Kosinski AS, Raymond DP, Broderick SR, Welsh RJ, DeCamp MM, Farjah F, Edwards MA, Kozower BD. Defining Proficiency for Society of Thoracic Surgeons Participants Performing Thoracoscopic Lobectomy. Ann Thorac Surg. 2019 Jan;107(1):202-208.
95. Que J, Garman KS, Souza RF, Spechler SJ. Pathogenesis and Cells of Origin of Barrett’s Esophagus. Gastroenterology. 2019 Aug 2019;157(2):349-364.
96. Quist J, Mirza H, Cheang MCU, Telli ML, O’Shaughnessy J, Lord CJ, Tutt ANJ, Grigoriadis A. A four-gene decision tree signature classification of triple-negative breast cancer: Implications for targeted therapeutics. Mol Cancer Ther. 2019 Jan;18(1):204-212.
97. Raj SD, Phillips J, Mehta TS, Quintana LM, Fishman MD, Dialani V, Slanetz PJ. Management of BIRADS 3, 4A, and 4B Lesions Diagnosed as Pure Papilloma by Ultrasound-Guided Core Needle Biopsy: Is Surgical Excision Necessary? Acad Radiol. 2019 Jul;26(7):909-914.
98. Raj SD, Agrons MM, Woodtichartpreecha P, Kalambo MJ, Dogan BE, Le-Petross H, Whitman GJ. MRI-guided needle localization: Indications, tips, tricks, and review of the literature. Breast J. 2019 May;25(3):479-483.
99. Raj SD, Shurafa M, Shah Z, Raj KM, Fishman MDC, Dialani VM. Primary and Secondary Breast Lymphoma: Clinical, Pathologic, and Multimodality Imaging Review. Radiographics. 2019 May-Jun;39(3):610-625.
100. Ravindranathan P, Pasham D, Goel A. Oligomeric proanthocyanidins (OPCs) from grape seed extract suppress the activity of ABC transporters in overcoming chemoresistance in colorectal cancer cells. Carcinogenesis. 2019 May 14;40(3):412-421.
101. Rini BI, Battle D, Figlin RA, George DJ, Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ, Pal SK, Pantuck AJ, Quinn DI, Seery V, Voss MH, Wood CG, Wood LS, Atkins MB. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). J Immunother Cancer. 2019 Dec 20;7(1):354.
102. Rizkalla J, Dauglas S, Nimmons S, El-Feky W, Syed I. Superior sulcus tumor disguised as cervical radiculopathy with metastasis to brachial plexus. Proc (Bayl Univ Med Cent). 2019;32(4):582-583.
103. Roy R, Kandimalla R, Sonohara F, Koike M, Kodera Y, Takahashi N, Yamada Y, Goel A. A comprehensive methylation signature identifies lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer. 2019 Mar 1;144(5):1160-1169.
104. Ruiz-Bañobre J, Goel A. DNA Mismatch Repair Deficiency and Immune Checkpoint Inhibitors in Gastrointestinal Cancers. Gastroenterology. 2019 Mar;156(4):890-903.
105. Saif MW, Rosen L, Rudek MA, Sun W, Shepard DR, Becerra C, Yamashita F, Bebeau P, Winkler R. Open-label study to evaluate trifluridine/tipiracil safety, tolerability and pharmacokinetics in patients with advanced solid tumours and hepatic impairment. Br J Clin Pharmacol. 2019 Jun;85(6):1239-1246.
106. Sakatani A, Sonohara F, Goel A. Melatonin-mediated downregulation of thymidylate synthase as a novel mechanism for overcoming 5-fluorouracil associated chemoresistance in colorectal cancer cells. Carcinogenesis. 2019 May 14;40(3):422-431.
107. Schmidinger M, Bamias A, Procopio G, Hawkins R, Sanchez AR, Vázquez S, Srihari N, Kalofonos H, Bono P, Pisal CB, Hirschberg Y, Dezzani L, Ahmad Q, Jonasch E; PRINCIPAL Study Group. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study; Hutson TE). Oncologist. 2019 Apr;24(4):491-497.
108. Schwartzberg L, McIntyre K, Wilks S, Puhalla S, O’Shaughnessy J, Berrak E, He Y, Vahdat L. Health-related quality of life in patients receiving first-line eribulin mesylate with or without trastuzumab for locally recurrent or metastatic breast cancer. BMC Cancer. 2019 Jun 13;19(1):578.
109. Shah NP, García-Gutiérrez V, Jiménez-Velasco A, Larson S, Saussele S, Rea D, Mahon FX, Levy MY, Gómez-Casares MT, Pane F, Nicolini FE, Mauro MJ, Sy O, Martin-Regueira P, Lipton JH. Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study. Leuk Lymphoma. 2019 Oct 24:1-10. doi: 10.1080/10428194.2019.1675879. [Epub ahead of print]
110. Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019 May;569(7754):131-135.
111. Smith MS, Cash B, Konda V, Trindade AJ, Gordon S, DeMeester S, Joshi V, Diehl D, Ganguly E, Mashimo H, Singh S, Jobe B, McKinley M, Wallace M, Komatsu Y, Thakkar S, Schnoll-Sussman F, Sharaiha R, Kahaleh M, Tarnasky P, Wolfsen H, Hawes R, Lipham J, Khara H, Pleskow D, Navaneethan U, Kedia P, Hasan M, Sethi A, Samarasena J, Siddiqui UD, Gress F, Rodriguez R, Lee C, Gonda T, Waxman I, Hyder S, Poneros J, Sharzehi K, Di Palma JA, Sejpal DV, Oh D, Hagen J, Rothstein R, Sawhney M, Berzin T, Malik Z, Chang K. Volumetric laser endomicroscopy and its application to Barrett’s esophagus: results from a 1,000 patient registry. Dis Esophagus 2019 Nov 13;32(9).
112. Snyder P, Dunbar K, Cipher DJ, Souza RF, Spechler SJ, Konda VJA. Aberrant p53 Immunostaining in Barrett’s Esophagus Predicts Neoplastic Progression: Systematic Review and Meta-Analyses. Dig Dis Sci. 2019 May;64(5):1089-1097.
113. Sonohara F, Gao F, Iwata N, Kanda M, Koike M, Takahashi N, Yamada Y, Kodera Y, Wang X, Goel A. Genome-wide Discovery of a Novel Gene-expression Signature for the Identification of Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma. Ann Surg. 2019 May;269(5):879-886.
114. Spechler SJ. Proton Pump Inhibitors: What the Internist Needs to Know. Med Clin North Am. 2019 Jan;103(1):1-14.
115. Sternberg CN, Motzer RJ, Hutson TE, Choueiri TK, Kollmannsberger C, Bjarnason GA, Paul Nathan, Porta C, Grünwald V, Dezzani L, Han J, Tannir NM. COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 Dec;17(6):425-435.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT42
116. Su T, Liu P, Ti X, Wu S, Xue X, Wang Z, Dioum E, Zhang Q. ΗΙF1α, EGR1 and SP1 co-regulate the erythropoietin receptor expression under hypoxia: an essential role in the growth of non-small cell lung cancer cells. Cell Commun Signal. 2019 Nov 21;17(1):152.
117. Su Q, Igyártó BZ. One-step artificial antigen presenting cell-based vaccines induce potent effector CD8 T cell responses. Sci Rep. 2019 Dec 12;9(1):18949.
118. Swink A, Nair A, Hoof P, Matthews A, Burden C, Johnson K, Blum JL. Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers. Proc (Bayl Univ Med Cent) 2019;32(3):340-344.
119. Takeda S, Shigeyasu K, Okugawa Y, Yoshida K, Mori Y, Yano S, Noma K, Umeda Y, Kondo Y, Kishimoto H, Teraishi F, Nagasaka T, Tazawa H, Kagawa S, Fujiwara T, Goel A. Activation of AZIN1 RNA editing is a novel mechanism that promotes invasive potential of cancer-associated fibroblasts in colorectal cancer. Cancer Lett. 2019 Mar 1;444:127-135.
120. Tan AR, Wright GS, Thummala AR, Danso MA, Popovic L, Pluard TJ, Han HS, Vojnović Ž, Vasev N, Ma L, Richards DA, Wilks ST, Milenković D, Yang Z, Antal JM, Morris SR, O’Shaughnessy J. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial. Lancet Oncol. 2019 Nov;20(11):1587-1601.
121. Toden S, Kunitoshi S, Cardenas J, Gu J, Hutchins E, Van Keuren-Jensen K, Uetake H, Toiyama Y, Goel A. Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer. JCI Insight. 2019 Mar 21;4(6).
122. Tripathi T, Yin W, Xue Y, Zurawski S, Fujita H, Hanabuchi S, Liu YJ, Oh S, Joo H. Central Roles of OX40L-OX40 Interaction in the Induction and Progression of Human T Cell-Driven Acute Graft-versus-Host Disease. Immunohorizons. 2019 Mar;3(3):110-120.
123. Wang W, Kandimalla R, Huang H, Zhu L, Li Y, Gao F, Goel A, Wang X. Molecular subtyping of colorectal cancer: recent progress, new challenges and emerging opportunities. Semin Cancer Biol. 2019 Apr;55:37-52.
124. Wang YZ, Chauhan A, Ramirez RA, Beyer DT, Stevens MA, Woltering EA, Boudreaux JP, Anthony L. Does the addition of adjuvant intraoperative tumor bed chemotherapy during midgut neuroendocrine tumor debulking procedures benefit patients? J Gastrointest Oncol. 2019 Oct;10(5):928-934.
125. Watson IT, DeCrescenzo A, Paek SY. Basal cell carcinoma within nevus sebaceous of the trunk. Proc (Bayl Univ Med Cent) 2019;32(3):340-344.
126. Weiss R 2nd, Read-Fuller A. Cone Beam Computed Tomography in Oral and Maxillofacial Surgery: An Evidence-Based Review. Dent J (Basel). 2019 May 2;7(2).
127. Wells KO, Senagore A. Minimally Invasive Colon Cancer Surgery. Surg Oncol Clin N Am. 2019 Apr;28(2):285-296.
128. Wells KO, Peters WR. Minimally Invasive Surgery for Locally Advanced Rectal Cancer. Surg Oncol Clin N Am. 2019 Apr;28(2):297-308.
129. Wen PY, Reardon DA, Armstrong TS, Phuphanich S, Aiken RD, Landolfi JC, Curry WT, Zhu JJ, Glantz M, Peereboom DM, Markert JM, LaRocca R, O’Rourke DM, Fink K, Kim L, Gruber M, Lesser GJ, Pan E, Kesari S, Muzikansky A, Pinilla C, Santos RG, Yu JS. A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma. Clin Cancer Res. 2019 Oct 1;25(19):5799-5807.
130. Weng W, Li H, Goel A. Piwi-interacting RNAs (piRNAs) and cancer: Emerging biological concepts and potential clinical implications. Biochim Biophys Acta Rev Cancer. 2019 Jan;1871(1):160-169.
131. Wilson TR, Udyavar AR, Chang CW, Spoerke JM, Aimi J, Savage HM, Daemen A, O’Shaughnessy JA, Bourgon R, Lackner MR. Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers. Mol Cancer Res. 2019 Jan;17(1):97-108.
132. Wu Y, Amonkar MM, Sherrill BH, O’Shaughnessy J, Ellis C, Baselga J, Blackwell KL, Burstein HJ. Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2019 Jun 1;30(6):1019.
133. Xie R, Yang Y, Zhang H, Liu H, Guo J, Qin H, Ma Y, Goel A, Li X, Wei Q. c-Myb and its Effector COX-2 as an Indicator Associated with Prognosis and Therapeutic Outcome in Colorectal Cancer. J Cancer. 2019 Feb 28;10(7):1601-1610.
134. Xiao H, Shiu PKT, Gabryleska M, Conn SJ, Dey A, Chakrabarti K, Regouc M, Pichler M, Ørom UAV, Santulli G, Nishiwada S, Goel A, Nagarajan V, Timmons L, Alahari SK, Laprovitera N, Ferracin M, Hu P, Jin H. The Non-Coding RNA Journal Club: Highlights on Recent Papers-7. Noncoding RNA. 2019 Jun 11;5(2)
135. Yamamura K, Izumi D, Kandimalla R, Sonohara F, Baba Y, Yoshida N, Kodera Y, Hideo B, Goel A. Intratumoral Fusobacterium nucleatum levels predict therapeutic response to neoadjuvant chemotherapy in esophageal squamous cell carcinoma. Clin Cancer Res. 2019 Oct 15;25(20):6170-6179.
136. Yang Y, Misra BB, Liang L, Bi D, Weng W, Wu W, Cai S, Qin H, Goel A, Li X, Ma Y. Integrated microbiome and metabolome analysis reveals a novel interplay between commensal bacteria and metabolites in colorectal cancer. Theranostics. 2019 May 31;9(14):4101-4114.
137. Yokomichi N, Nishida N, Umeda Y, Taniguchi F, Yasui K, Toshima T, Mori Y, Nyuya A, Tanaka T, Yamada T, Yagi T, Fujiwara T, Yamaguchi Y, Goel A, Kudo M, Nagasaka T. Heterogeneity of Epigenetic and Epithelial Mesenchymal Transition Marks in Hepatocellular Carcinoma with Keratin 19 Proficiency. Liver Cancer. 2019 Jul;8(4):239-254.
138. Zhang Q, Agoston AT, Pham TH, Zhang W, Zhang X, Huo X, Peng S, Bajpai M, Das K, Odze RD, Spechler SJ, Souza RF. Acidic Bile Salts Induce Epithelial to Mesenchymal Transition via VEGF Signaling in Non-Neoplastic Barrett’s Cells. Gastroenterology. 2019 Jan;156(1):130-144.
139. Zhao L, Wang W, Xu L, Yi T, Zhao X, Wei Y, Vermeulen L, Goel A, Zhou S, Wang X. Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. Oncogene. 2019 Mar;38(13):2305-2319.
BAYL
OR
UN
IVER
SITY
MED
ICA
L C
ENTE
R
2019
ON
CO
LOG
Y A
NN
UAL
REPO
RT
43
Photography may include models or actors and may not represent actual patients. Physicians provide clinical services as members of the medical staff at one of Baylor Scott & White Health’s subsidiary, community or affiliated medical centers and do not provide clinical services as employees or agents of those medical centers, Baylor Health Care System, Scott & White Healthcare or Baylor Scott & White Health. ©2020 Baylor Scott & White Health. BSWSAMCC_70_2019 BID
CANCER HATES DEFENDERS
Because they’re relentless. Nurse navigators like Stacey Webb are advocates for patients giving them the encouragement to not only survive but thrive.
214.820.3535 Patient NavigationBSWHealth.com/DallasCancer